**Name of Journal:** *World Journal of Stem Cells*

**Manuscript NO:** 79441

**Manuscript Type:** REVIEW

**Profile of biological characterizations and clinical application of corneal stem/progenitor cells**

Ying PX *et al*. Corneal stem/progenitor cells’ profile and application

Pei-Xi Ying, Min Fu, Chang Huang, Zhi-Hong Li, Qing-Yi Mao, Sheng Fu, Xu-Hui Jia, Yu-Chen Cao, Li-Bing Hong, Li-Yang Cai, Xi Guo, Ru-Bing Liu, Fan-ke Meng, Guo-Guo Yi

**Pei-Xi Ying,** Department of Ophthalmology, Zhujiang Hospital, The Second Clinical School, Southern Medical University, Guangzhou 510280, Guangdong Province, China

**Min Fu,** Department of Ophthalmology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, Guangdong Province, China

**Chang Huang,** Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai 200030, China

**Chang Huang,** NHC Key Laboratory of Myopia, Fudan University, Shanghai 200030, China

**Chang Huang,** Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai Key Laboratory of Visual Impairment and Restoration, Shanghai 200030, China

**Zhi-Hong Li,** Department of Cardiology, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Lab of Shock and Microcirculation, Nanfang Hospital, Southern Medical University, Guangzhou 510550, Guangdong Province, China

**Qing-Yi Mao, Xu-Hui Jia, Yu-Chen Cao, Li-Bing Hong, Li-Yang Cai, Ru-Bing Liu,** The Second Clinical School, Southern Medical University, Guangzhou 510515, Guangdong Province, China

**Sheng Fu,** Hengyang Medical School, The University of South China, Hengyang 421001, Hunan Province, China

**Xi Guo,** Medical College of Rehabilitation, Southern Medical University, Guangzhou 510515, Guangdong Province, China

**Fan-ke Meng,** Emergency Department, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, Guangdong Province, China

**Guo-Guo Yi,** Department of Ophthalmology, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou 510655, Guangdong Province, China

**Author contributions:** Ying PX, Mao QY, Huang C, Fu M, and Yi GG designed the research study; Jia XH, Cao YC, Hong LB, Cai LY, Guo X, Liu RB, Meng FK, Fu M, and Yi GG provided help and advice; Ying PX, Fu M, Mao QY, Huang C, Li ZH, and Fu S wrote the manuscript; all authors have read and approved the final manuscript.

**Corresponding author: Guo-Guo Yi, MMed, Attending Doctor,** Department of Ophthalmology, The Sixth Affiliated Hospital of Sun Yat-sen University, No. 26 Erheng Road, Yuancun, Guangzhou 510655, Guangdong Province, China. yigg@mail.sysu.edu.cn

**Received:** August 21, 2022

**Revised:** November 8, 2022

**Accepted:** November 23, 2022

**Published online:** November 26, 2022

**Abstract**

Corneal stem/progenitor cells are typical adult stem/progenitor cells. The human cornea covers the front of the eyeball, which protects the eye from the outside environment while allowing vision. The location and function demand the cornea to maintain its transparency and to continuously renew its epithelial surface by replacing injured or aged cells through a rapid turnover process in which corneal stem/progenitor cells play an important role. Corneal stem/progenitor cells include mainly corneal epithelial stem cells, corneal endothelial cell progenitors and corneal stromal stem cells. Since the discovery of corneal epithelial stem cells (also known as limbal stem cells) in 1971, an increasing number of markers for corneal stem/progenitor cells have been proposed, but there is no consensus regarding the definitive markers for them. Therefore, the identification, isolation and cultivation of these cells remain challenging without a unified approach. In this review, we systematically introduce the profile of biological characterizations, such as anatomy, characteristics, isolation, cultivation and molecular markers, and clinical applications of the three categories of corneal stem/progenitor cells.

**Key Words:** Corneal epithelial stem cells; Corneal endothelium stem cells; Corneal stromal stem cells; Bioengineering; Gene markers

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Ying PX, Fu M, Huang C, Li ZH, Mao QY, Fu S, Jia XH, Cao YC, Hong LB, Cai LY, Guo X, Liu RB, Meng FK, Yi GG. Profile of biological characterizations and clinical application of corneal stem/progenitor cells. *World J Stem Cells* 2022; 14(11): 777-797

**URL**: https://www.wjgnet.com/1948-0210/full/v14/i11/777.htm

**DOI**: https://dx.doi.org/10.4252/wjsc.v14.i11. 777

**Core Tip:** The manuscript systematically reviewed three categories of stem cells or progenitor cells in cornea (including corneal epithelial stem cells, corneal endothelial cell progenitors and corneal stromal stem cells). There are two aspects of the manuscript that will make it interesting to general readers. Not only have we systematically introduced the anatomy, characteristics, cultivation and gene markers of these corneal stem cells, but also highlighted the bioengineering in the clinical application of these corneal stem cells. In addition, this manuscript is accompanied by beautiful figures and tables.

**INTRODUCTION**

The cornea acts as a structural barrier to protect the eye from the outside environment. Transparency of the cornea allows the light to enter the retina and has a very good ability to refract. The cornea is elliptical-shaped horizontally, 11.5-12.0 millimetres long horizontally and 10.5-11.0 millimetres long vertically[1]. The thickness of the cornea increases gradually from the centre (approximately 0.5 millimetres) to the periphery (approximately 1 millimetre)[2]. The cornea accounts for two-thirds of the refractive power of the eye, which is why corneal integrity is important for the maintenance of vision[3].

The cornea is composed of cellular and acellular components. Cell components include epithelial cells, keratocytes and endothelial cells as well as neural and immune cells[4]. The cell-free components include collagen and glycosaminoglycans. Corneal epithelial cells are derived from the epidermal ectoderm, while stromal cells and endothelial cells are derived from the neural crest. The corneal layer includes the epithelium, Bowman membrane, stroma, Descemet membrane and endothelium (Figure 1).

Recovery after corneal injury depends mainly on the regeneration of stem cells or progenitor cells. Corneal trauma and disease are highly associated with fibrosis, which can easily lead to severe visual impairment. In particular, the lesions of the central part of the cornea will seriously affect vision. After the corneal epithelium is damaged, it can regenerate without scarring[3]. However, when the damage affects Bowman’s layer, its ability to regenerate is very limited, and Bowman’s layer will be replaced by scar tissue. The stromal layer plays an important role in maintaining corneal transparency and resisting intraocular pressure and is also repaired by scar tissue after injury, resulting in the loss of transparency. The injury of Descemet’s membrane can be regenerated by endothelial cells. In the past, damage to the endothelium was generally believed to be difficult to regenerate and could only cover the deficit left by injury through cell enlargement and migration. Although still controversial, in recent years, there has been increasing evidence supporting the existence of corneal endothelial progenitor cells[5-7].

At present, the most commonly used method to treat corneal injury is corneal transplantation, and research on stem cells or progenitor cells will provide great help. In 1971, Wolosin *et al*[8] proposed the concept of limbal stem cells (LSCs), suggesting that epithelial corneal stem cells exist in the limbal gland. LSC deficiency (LSCD) is a serious disease that causes permanent corneal injury and visual loss due mainly to various kinds of corneal injuries and chronic immune diseases. LSCD has become a hot research direction in recent years, and new treatments are emerging. LSCs play an important role in repairing various kinds of corneal injuries and chronic immune diseases. In 2005, Du *et al*[9] found the first stem cell-like precursor cells of human corneal stromal cells. Similarly, corneal endothelial progenitors with the ability to self-renew and differentiate into mature corneal endothelial cells have also been identified, although corneal endothelial cells were widely believed not to be able to regenerate in humans. These stem cells have attracted great attention from the public, and an increasing number of people have devoted themselves to the study of their anatomy, physiology, immunology, cell culture and isolation.

It is essential to understand the anatomy, characteristics, methods of isolation and cultivation, molecularmarkers and therapeutic potential and applications of corneal stem/progenitor cells. We briefly discuss the three types of stem/progenitor cells of the cornea in this review.

**Corneal epithelial stem cells**

***Anatomy***

Human corneal epithelial stem cells have been proven to be situated in the basal layer of the limbal epithelium, so they are also known as LSCs[10]. Pathologically, it is generally believed that the anterior limbus is situated in the plane connecting the end of the Bowman membrane and the Descemet membrane, while the posterior limbus is located in the plane passing through the iris root and perpendicular to the ocular surface. In addition, ophthalmic surgeons should be proficient in the gross anatomy of the limbal, which is the incision for most cataract and glaucoma surgeries. Surgically, limbus is known as the grey or blue zone because this transition zone shows a blue-grey appearance when viewed externally after the conjunctiva has been reflected away from the limbus[11].

Moreover, due to high vascularization and neuralization, the limbus is nutrient-rich and perceptive, and protected from potential ultraviolet (UV) damage by melanin pigmentation[4]. The corneal epithelial stem cell region is only 1.5-2.0 mm wide in the basal layer of the corneal epithelium, a small portion of the entire tissue, and is estimated to account for 0.5% or less to 10.0% of the total number of cells in palisades of Vogt[8,12,13] (Figure 2).

Cell migration is one of the most basic elements of epithelial homeostasis. A mathematical analysis of the kinetics of maintenance of corneal epithelial mass confirms that the corneal epithelium can be maintained by the centripetal migration of epithelial cells of limbal origin[14,15]. Currently, it is widely accepted that LSCs generate transient amplifying cells (TACs), which then migrate centripetally and anteriorly to give rise to differentiated corneal epithelial cells that eventually fall off the surface of the cornea, as proposed in the X-Y-Z hypothesis[16,17]. LSCs are particularly important in maintaining corneal epithelial homeostasis and normal corneal wound healing. In addition, acute damage to the central cornea can be repaired by the proliferation and migration of central corneal epithelial cells[18].

***Characteristics***

**Low differentiation with a primitive phenotype:** Stem cells have long been recognized to be primitive cells with little differentiation. In 1986, Schermer *et al*[19] proposed the limbal location of corneal stem cells based on differentiation-related expression of 64K keratin. Immunohistochemical data showed that limbal basal cells were the least differentiated of all corneal epithelial cells. Moreover, cytokeratin K3 and K12, as specific markers of the corneal epithelial phenotype, were not expressed in limbal basal epithelial cells. Therefore, many studies have also confirmed the low differentiation phenotype of LSCs[20,21]. Many studies have shown that some materials or cells [such as Frizzled 7, HC-HA/PTX3 and human limbal melanocytes (hLM)] can maintain the low differentiation state of LSCs[22] (Niche regulation of limbal epithelial stem cells: HC-HA/PTX3 as a surrogate matrix niche)(Limbal melanocytes support limbal epithelial stem cells in 2D and 3D microenvironments).

**Long cell cycle and high proliferative potential:** A long cell cycle indicates low mitotic activity. Most stem cells are in a state of steady growth, so the proliferation rate is extremely low[23]. However, the high proliferative potential of stem cells can be activated under injury or *in vitro* culture. Taking advantage of several animal models and *ex vivo* human limbal cultures, the existence of slow-cycling and label-retaining cells in the basal layer of the limbal basal epithelium was proven by previous studies[24-27]. Multiple studies on proliferation potential in the presence of injury, absence of injury, *in vitro* culture, or differentiation-inducing agents have further supported the idea that corneal epithelial stem cells are located in the limbus[28-32]. Recent studies by Sagga *et al*[33] quantified the proliferative dynamics of LSCs during corneal wound healing. They found that the cell circulation of central corneal epithelial cells in young mice (4.97 d ± 0.50 d) was significantly slower than that in ageing mice (3.24 d ± 0.20 d). In wounded eyes, the proportion of LSCs entering S phase within 24 h in young mice increased 7 times compared with that in uninjured mice, but no significant increase was observed in aging mice. The contribution of LSCs in regenerative ophthalmology has demonstrated that LSCs can also be used to reconstruct the entire corneal epithelium in the case of severe ocular surface injury[34]. Additionally, the location of corneal epithelial stem cells in the limbus may account for the relative superiority of limbal neoplasms and the rarity of corneal epithelial tumours[35-37].

**Capacity for unlimited self-renewal and error-free proliferation:** According to the result of division, the division of stem cells is divided into symmetric division and asymmetric division. Symmetric division occurs when a stem cell divides into two identical daughter stem cells, while asymmetric division occurs when a stem cell divides into two different cells. Lamprecht *et al*[38,39] first reported asymmetric division of mammalian corneal epithelial stem cells. Using differences in cell size, nuclear chromatin condensation, and cytoplasm density as criteria for histological analysis, they found that mitosis of corneal epithelial stem cells can be classified according to the position relationship between the spindle axis and basal lamina: Vertical mitosis (spindle axis at 60-90 degrees from basal lamina); oblique mitosis (spindle axis at 30-60 degrees from basal lamina); horizontal mitosis (spindle axis 0-30 degrees from basal lamina). Among these relationships, the daughter cells produced after horizontal mitosis were all located in the basal lamina, and their morphology and proliferation ability were similar to that before mitosis. The daughter cells produced after vertical mitosis and oblique mitosis were different in morphology and proliferation potential. The cells located in the basal lamina still had proliferation ability, while the cells located above the basal lamina developed towards the direction of terminal differentiation. The asymmetric division of corneal epithelial stem cells not only contributes to the replenishment of the stem cell pool but can also renew the corneal epithelium in time to cope with accidents or diseases such as corneal injury. This process of division does not allow errors because any genetic error at the stem cell level will continue to be transmitted to the entire cell clone, leading to abnormal differentiation and cellular dysfunction.

**Morphological criteria:** Both confocal microscopy and flow cytometry have shown that the smallest cells are located in the limbal basal epithelium rather than the corneal basal epithelium[40]; electron microscopy showed that limbal epithelial basal cells were characterized by immature cells, such as small cells, rich in tonofilaments in the cytoplasm, euchromatin-rich nuclei, almost undetectable nucleoli and a high nuclear-cytoplasmic ratio[41].

***Isolation and cultivation***

There are numerous of ways to isolate cells, one of which uses enzymes. In 2010, Yamamoto *et al*[42] cultured human corneal epithelial cells in serum-free medium by an enzyme-treated cell culture method. The corneal epithelium was separated from the limbus of the corneal peripheral area, and the corneal endothelium was removed. The limbus was then carefully separated from the underlying matrix with 0.25% collagenase and Accumax (cell aggregation disintegration medium). Finally, corneal epithelial cells were cultured in serum-free PCT corneal epithelial medium. The results showed that compared with human corneal epithelial cells (HCEC2 cells), the survival rate of the corneal epithelial cells obtained in this experiment increased significantly after being cultured on CNT-20 medium to the sixth generation, indicating that the enzyme separation method could maintain cell viability.

Recent studies have shown that flow cytometry and immunofluorescence activation can be used to isolate cells. Shaharuddin *et al*[43] isolated and identified LSCs using an optimized limbal side population (LSP) regimen, including an optimized Hoechst concentration, Hoechst incubation time and inhibitor concentration. After preoptimization, cells isolated from tissues were bound to a DNA-binding dye, Hoechst 33342, mediated by a TP-binding box (ABC) transporter. Then, two types of cells, Hoechst Blue (SP) and Hoechst Red (non-SP), were obtained by flow cytometry analysis and fluorescent-activated cell sorting. Compared with non-SP cells, the expression of the stem cell markers ABCG2, ΔNp63 and SOX2 was significantly higher in SP cells according to the immunofluorescence assay. Shaharuddin *et al*[43] demonstrated that the LSP protocol identifies and enriches LSCs by preoptimizing key parameters.

Based on previous studies, Nam *et al*[44] cultured corneal epithelial cells on the canine amniotic membrane. Under a light microscope, the cultured cells fused 100% after 7-8 d, and 5-8 Layers of epithelial cells were formed on the amniotic membrane. K3 (a corneal epithelial-specific marker) was observed in all cultures by immunofluorescence, while ABCG2, P63, and vimentin (a stem cell marker) were observed only in the basal layer. The results showed that beagle corneal epithelial cells could be cultured on the canine amniotic membrane, and the basal layer cells might be stem cells. Moriyama *et al*[45] cultured equine LSCs in standard supplemental hormone epithelial medium (SHEM). Cells isolated from LEC tissue extracted from the limbs were cultured in standard SHEM. Immunostaining showed positive p63, CK14, and negative CK3 cells, similar to the expression pattern of limbal epithelial basal cells, suggesting that LSCs could be obtained by this method.

In addition, different temperatures also affect the separation from the cells. Nam *et al*[46] compared the effects of different media (canine amniotic membrane, heterotopic collagen gel, temperature-sensitive culture dish) on corneal stem cell culture. Cells were isolated from beagle corneal epithelial cells and cultured on canine amniotic membrane, collagen gel and temperature-sensitive culture dishes. Ki-67, K3, ABCG2 and P63 were used as indices. Immunofluorescence and real-time quantitative polymerase chain reaction (RT-PCR) were used to observe the culture time and the number of cell layers adhered to and fused. The specific results are shown in Table 1.

RT-PCR showed that the expression level of ABCG2 mRNA was 9.9 times larger on the canine amniotic membrane than on the atelocollagen gel and 7.2 times larger than on the temperature-responsive culture dish. The expression level of P63 on atelocollagen gel was 2.8 times and 3.2 times higher than that on canine amniotic membrane and temperature-responsive culture dishes, respectively. The atelocollagen gel-cultured corneal epithelium showed morphology similar to the normal corneal epithelium and retained more stem cells/progenitors than the canine amniotic membrane and temperature-responsive culture dish.

Compared to the canine amniotic membrane, the human amniotic membrane (HAM) is the most common scaffold for culture, both experimentally and clinically. Kim and Tseng[47] were the first to use HAM for clinical treatment. They transplanted HAM alone into corneas with mild LSCD that did not require LSC treatment to promote re-epithelialization. Subsequently, researchers began to study the possibility of HAM as an amplification carrier of LSCs. From the early coculture with the mouse 3T3 fibroblast feeding layer[48], animal-free amplification methods have been designed to avoid the risk of zoonosis[49,50]. With the deepening of the research, HAM was found to have increasing advantages in the aspect of corneal transplantation, including anti-inflammatory, antimicrobial, antiangiogenesis, antifibrosis, secretion of neurotransmitters and growth factors, finally reducing scar formation, stimulating the epithelialization and differentiation of corneal epithelial cells as well as enhancing adhesion and preventing apoptosis[51,52]. Today, HAM can play a role in a variety of corneal injury diseases or postoperative treatment, including refractory corneal ulcers and corneal epithelial defects, malignant tumours or pterygium resection[53].

The above studies (Table 2) provide a variety of methods for the isolation and culture of LSCs. Enzymatic dissociation is one of the most common methods to disperse tissues into single cells[54-56]. According to the differences in cell and interstitial composition between different tissues, trypsin or collagenase digestion is used to achieve cell separation. Compared with separating cells with only enzymes, the LSP protocol preoptimizes the concentration of dyes and inhibitors, staining time, *etc.*, which is beneficial to the identification and enrichment of LSCs. In the cultivation of LSCs, a variety of substances can be used as culture media for LSCs, such as media supplemented with hormones, animal materials (canine amniotic membrane), HAM, collagen gels and temperature-responsive culture dishes. Compared with animal materials and temperature-responsive culture dishes, cells cultured in collagen gel are more similar in morphology to normal corneal epithelial cells and contain more stem cells.

However, there are some disadvantages in culturing LSCs with HAM and animal materials. For example, the amniotic membrane has obvious biodegradation and immunosuppressive properties during transplantation. Its thickness and variable transparency are also disadvantages. Moreover, the use of feeder cells or a composite medium containing growth factors or animal materials may also cause biological contamination or other safety issues(such as prion transfer or unknown diseases)[57-62]. Therefore, more improvements or alternative methods are needed.

***Molecular markers for LSCs***

**Cytoskeletal proteins:** In recent years, corneal transplantation has become a research hotspot of corneal epithelial stem cell gene markers. Moriyama *et al*[45] studied the eye tissues of 12 adult thoroughbred horses. They used immunohistochemical staining for negative markers (CK3) and positive markers (P63, CK14)[63] to determine the distribution and culture of equine corneal epithelial stem cells (CESCS). The experimental results showed that P63 played an important role in the proliferation of human keratinocytes and was expressed in basal cells of various human epithelial tissues and was a stem cell marker[64]. Moreover, the results indicated that 13,14,24-26,31,33 CK14[65] is a useful indicator for the identification of epithelial progenitor cells with basal cell activity, as well as a marker of stem cells. In addition, among these stem cell markers, antihuman P63, antiCK14, and CK3 antibodies can cross-react with equine corneal epithelial cells[66]. These research results are of great significance for follow-up clinical treatment.

**Cytosolic proteins:** Lyngholm *et al*[67] used a proteomics method combining two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) to study the difference in protein expression between human central corneal epithelium and limbal epithelial cells. A total of 25 different proteins were identified. Superoxide dismutase 2 (SOD2) is expressed in the basal limbal epithelial cell population; heat shock protein 70 protein 1 (HSP70.1) and annexin I are expressed at higher levels in the limbal epithelium, but there is also a small amount of expression in the central epithelium. They also found that SOD2 appears almost exclusively in the limbal epithelium of the basal cornea. SOD2 induces phosphorylation and activation of mitogen-activated protein kinases (MAPKs) by regulating H2O2 and activates signalling molecules, including extracellular regulatory kinases (ERKs) and c-Jun N-terminal kinase (JNK)[68].

In addition, the Notch-1 gene plays an important role in corneal stem cell transplantation, and related research on this gene has also been reported in recent years. For example, Thomas *et al*[69] obtained human corneoscleral tissue from the Doheny Eye & Tissue Transplant Library through explant culture and primary culture and performed cross-sectional and full-thickness analysis. Their experiment studied mainly the expression of Notch 1 in the basal epithelium of the limbus, and the results showed that Notch-1 was expressed in the area of limbus stem cells. The antigenicity of Notch-1 is more obvious in the cell mass, mainly in the fence of Vogt. There is almost no Notch-1 in the centre of the cornea. In addition, ABCG2[70] and Notch1 double staining showed that some ABCG2-positive cells coexpressed Notch-1 in the limbus basal epithelium, suggesting that Notch-1-expressing cells may be a unique subgroup with stem cell characteristics. This result suggests that further research and characterization of the Notch pathway will provide valuable clues for clinical research on stem cell transplantation.

**Neuronal markers:** In addition, the interaction between KLF, PAX-6 and ESE-1 has important research value in human corneal development and physiology. The regulation of KLF family members by K12 is closely related to cell growth, proliferation and proliferation. GKLF/KLF4 participates in p53transactivation of p21 WAF1/Cip1 promoter induction, cyclin D1 promoter activity inhibition and cell proliferation inhibition, which indicates that this protein may play a direct role in negative growth control[71]. A recent study found that KLF4 can block the epithelial to mesenchymal transition (EMT) of human corneal epithelial cells (HCECs) by inhibiting the canonical TGF-β signalling pathway. Therefore, KLF4 plays a crucial role in the maintenance of HCEC homeostasis and has the potential to prevent the formation of corneal fibrosis scars[72].

**Pinin:** Pinin (PNN) is an exon junction component (EJC) that is important in the differentiation of corneal epithelial cells and can act as a stabilizer for the corneal epithelial phenotype. Using RNA-seq to obtain the results, PNN knockout-upregulated genes included a large number of genes related to cell migration and ECM remodelling processes, such as MMPs, ADAMs, HAS2, LAMA3, CXCRs, and UNC5C. Genes knocked down by PNN gene knockout included IGFBP5, FGD3, FGFR2, PA X6, RARG, and SOX10[73].

***Recent research on LSC deficiency***

**Causes of LSC deficiency:** LSCD is a pathological condition caused by dysfunction and/or insufficient quantity of LSCs, which is marked by impaired barrier function of the limbus and the replacement of corneal epithelium by conjunctival epithelial cells[74,75]. Direct damage to LSCs and/or destruction of their niche microenvironment is the causes of their pathogenesis. Loss of stem cells due to severe damage to the limbal can result in permanent corneal epithelial defects and vision loss due to the conjunctiva[76]. Moreover, although LSCD can be divided into unilateral LSCD and bilateral LSCD, their causes are similar. Burns are the most common cause, followed by Stevens-Johnson syndrome (SJS), atopic keratoconjunctivitis (AKC)/vernal keratoconjunctivitis (VKC) and mucous membrane pemphigoid (MMP). Since congenital aniridia is a disorder of two eyes caused by haploinsufficiency of the Pax6 gene, it is only the cause of bilateral LSCD[77]. Additionally, the primary burns are alkali burns. Thermal burns, acid burns, radiation burns and others account for only a small percentage[78,79]. The conditions that lead mainly to LSCD include two main categories, hereditary LSCD and acquired LSCD, as shown in Table 3[80-115].

**Diagnosis of LSCD:** The main symptoms and signs of LSCD are[75,116]: (1) Nonspecific symptoms, including vision loss, photophobia, lacrimatorrhea, blepharospasm, redness associated with chronic inflammation, and recurrent episodes of pain caused by epithelial lesions; (2) signs: Under a slit-lamp biomicroscope, the corneal epithelium shows three grades of damage including mild, moderate and severe/total LSCD: Mild grade: Dull or irregular corneal surface without light reflex, opaque corneal epithelium and deterioration of limbal palisades of Vogt; moderate grade: A vortex pattern of abnormal epithelium with fluorescein staining, superficial vascularization of the cornea and peripheral pannus; and severe grade: Thick fibrous pannus formation, chronic keratitis, scarring and corneal conjunctivization; and (3) the migration of conjunctiva and goblet cells to the corneal surface was confirmed by impression cytology.

In addition, there are some new advances in the diagnosis of LSCD involving *in vivo* laser scanning confocal microscopy and anterior segment optical coherence tomography.

**Basic treatment principles and methods of LSCD:** Treatment strategies for LSCD can generally be divided into two categories: (1) Conservative treatment, including conservative nonsurgical options and conservative surgical options; and (2) Invasive treatment, which means transplantation aimed at repairing the structure and function of the corneal epithelium[117] (Table 4).

Conservative treatment: (1) Conservative nonsurgical options: Autologous serum drops[118], therapeutic soft contact lenses[119], therapeutic scleral lenses and eye lubrication[114]; (2) conservative surgical options: Corneal scraping[120] and amniotic membrane transplantation (AMT)[53,121]. AMT is effective in patients with partial or mild LSCD[122]. However, long-term debilitated vision remained in those with severe LSCD caused by burns[123]. In recent years, LSC deficiency has been successfully treated by direct transplantation of a portion of healthy limbal tissue or LSC, even some other alternative cells populations.

Transplantation: (1) Conjunctival limbal autograft (CLAU)[124,125]; (2) conjunctival limbal allograft (CLAL)[86,126];(3) keratolimbal allograft (KLAL)[127,128]; (4) *ex vivo* cultivated limbal epithelial stem cells (CLET); (5) simple limbal epithelial transplantation (SLET); and (6) alternative cell population transplantation. In CLAU, CLAL and KLAL, since the long time for limbus transplantation from the donor to the stem cell deficient eye, healthy donor eyes have an increased risk of LSCD. In addition, the application of immunosuppressants in CLAL and LSCD may increase the risk of infection or cancer. CLET is a technique in which autologous or allogeneic LSCs are cultured on a carrier for transplantation, which greatly reduces the incidence of LSCD in healthy donors[129,130]. In addition, since LSCs cultured *ex vivo* do not differentiate into Langerhans cells, the incidence of immune rejection will also be decreased. SLET is a technique to evenly distribute autologous limbal tissue and attach it to HAM for transplantation. SLET not only holds the advantages of CLET in reducing the incidence of LSCD and immune rejection but also avoids the difficulties of *ex vivo* culture technology, which achieves higher economic benefits[131-133]. However, the risk of disease transmission is increased due to the application of carriers such as the HAM[134].

**Emerging alternative therapies for LSCD:** In addition to the above traditional treatments for LSCD performing limbal tissue or stem cell transplantation, advances in tissue engineering have led to the development of a growing number of emerging therapies, including alternative cell populations and alternative cell carriers/scaffolds.

Alternative cell populations: Compared with traditional transplants, the application of alternative cell populations avoids corneal donor shortages and the risk of disease transmission, graft rejection and tumours (due to immunosuppressant application) associated with allografts, which makes it possible to replace traditional transplants. Currently, the alternative cell populations include oral mucosal epithelial cells[135,136], human embryonic stem cells (HESCs)[137], induced pluripotent stem cells (iPSCs)[138,139], mesenchymal stem cells (MSCs)[140,141], human immature dental pulp stem cells[142,143], *etc.* Among these alternatives, MSCs and iPSCs are of vital importance and will be described in detail.

MSCs are a population of proliferative and multipotent stem cells present in various tissues throughout development. In the cornea, MSCs are natural residents of the LSC niche and can modulate immune response *via* paracrine action[144]. Additionally, MSCs have been shown to reduce neovascularization, stromal opacification, inflammation, and corneal oedema in animal models of LSCD secondary to chemical or mechanical injury, which offers advantages in corneal reconstruction[145,146]. The therapeutic effect of MSCs in regenerative corneal therapy can be attributed to direct cell replacement[147], differentiation into corneal epithelial-like cells[148] and secretion of soluble factors to regulate tissue wound repair, inflammation, angiogenesis and the immune response. Many studies have shown that MSCs have a wide range of applications, whether *in vivo* or *in vitro*, to help repair corneal epithelium[148-151], corneal stroma[152,153] and even corneal endothelium[154]. Therefore, MSCs have the potential to be differentiated into corneal cell types and can be potential candidates for regeneration of the cornea.

iPSCs are a population with pluripotent capacity to differentiate into many cell types and are generated from embryonic or adult body cells[155,156]. In 2006, the iPSC technique was first reported by Takahashi and Yamanaka, who dedifferentiated mouse fibroblasts into embryonic stem cell-like cells, which they named “iPSCs”[155]. iPSCs have self-renewing and multidirectional differentiation potential, which could generate corneal organoids expressing markers of adult corneal tissue[157] and displaying similar features of the developing cornea[158]. iPSCs are easy to obtain, and their autologous transplantation can avoid immune rejection, which has good prospects in the treatment of LSCD in the future.

Alternative cell carriers/scaffolds: HAM is the most commonly used cell carrier for ocular surface reconstruction. However, due to the disadvantages of HAM (such as high thickness, variable transparency, biodegradation and immunosuppression), it is urgent for us to find alternative cell carriers/scaffolds to substitute for HAM. At present, alternative cell carriers/scaffolds contain modified HAM, collagen[159,160], fibrin[161], siloxane hydrogel contact lenses, human lens capsules, poly (ε-caprolactone)[162], onion epithelial membrane scaffolds[163], carboxymethyl cellulose (CMC)[164], electrospun polycaprolactone/gelatine nanocomposites[165] and other emerging materials. The modified HAM will be described in detail below.

Modified HAM is initiated by chemical modification of HAM to avoid or mitigate the above shortcomings. Chemically modified HAMs have been developed using cross-linking agents, including glutaraldehyde[166], carbodiimide[167,168] and aluminium sulfate. Compared with glutaraldehyde, carbodiimide has lower cytotoxicity and the addition of L-lysine enhances the mechanical and thermal strength, the ability to support LESCs and the enzyme digestion resistance of HAM[169]. Additionally, aluminium sulfate cross-linked HAM remains sterile and shows increased tensile strength during 12 mo of storage[170].

Albert *et al*[171] cultured LSCs in animal-free medium-that is, the lens capsule with human serum as the only growth supplement. The results showed that the viability of LSCs cultured on human LC was greater than 97% at the two checkpoints (day 7 and day 14), and the percentages of early apoptotic cells and late apoptotic cells were lower. Immunofluorescence showed that the resulting cells maintained their pluripotency by maintaining p63, ABCG2, CK19, Vim and Itg9 and low ck3/12 expression. The presence of differentiation characteristics (positive for CK8/18 and CK14) also indicates its potential for orthotopic differentiation into the corneal epithelium. All the above results indicated that LSCs could be cultured from lens capsules using human serum as the only growth supplement without the disadvantage of animal medium.

**Corneal stromal stem cells**

***Anatomy***

The stroma, which makes up approximately 90% of the cornea, is a collagenous mesenchymal tissue composed of approximately 200 orthogonally oriented lamellae. Each lamella is made up of long uniform collagen fibrils lying parallel to one another with regular interfibril spacing, which is essential in rendering the tissue transparent[172]. Many fibroblast-like cells distributed in the matrix are commonly known as corneal stromal cells. The corneal stroma is derived from the neural crest, which is the source of mesenchymal tissue in the head and neck. Corneal stromal cells have extensive cytoplasmic processes in contact with similar processes in neighbouring cells.

By staining with ABCG2 and PAX6 proteins, corneal stromal stem cells were observed largely in the transitional zone between the cornea and sclera known as the limbus[173]. More specifically, CSSCs are in the anterior stroma subjacent to the epithelial basement membrane, in regions where the basement membrane has Muslimah and folds termed the Palisades of Vogt (Figure 2)[173,174].

***Characteristics***

Under normal physiological conditions, corneal stromal cells remain stationary in mitosis and maintain a highly ordered layer of collagen and proteoglycan, which are essential for providing corneal transparency. In addition, they are often characterized by molecular markers, including aldehyde dehydrogenase (ALDH), crystallins, CD133, and CD34[175]. When the cornea is injured corneal stromal cells are activated and lose the expression of cellular markers and adopt fibroblasts and myofibroblasts to form scar phenotypes.

***Bioengineering corneal tissue with stromal stem cells***

The highly ordered hierarchical ultrastructure of the corneal matrix, which exhibits exceptional biomechanical properties and optical transparency, makes it one of the most challenging steps in engineering human corneal tissue[176]. Fortunately, in 2005, Du *et al*[9] identified the first stem cell-like human corneal stromal cell precursors. The study found that in serum-free medium, human corneal stromal stem cells (hCSSCs) differentiate into cells expressing a gene profile similar to the profile of human keratocytes and secrete multilayered lamellae with orthogonallyoriented collagen fibrils similar to the corneal stroma, when cultured as floating pellets in the absence of rigid scaffolding or substratum[177].

Furthermore, some studies have found that CSSCs may not only have the ability of immune privilege but also have the potential to provide direct cell therapy pathways. The ability of CSSCs to exhibit immune privilege makes them excellent candidates for the generation of bioengineered corneal stromal constructs. Du *et al*[175] found that after direct injection into mouse corneas with scars, both the organization and transparency of the cornea were successfully restored without eliciting an immune T-cell response. Similarly, Ghoubay *et al*[178] developed a mouse model of corneal stromal scarring induced by liquid nitrogen (N2) application. Through direct injection of mouse or human corneal stromal stem cells in this model, they found that the transparency of the injured cornea was improved, the inflammatory response disappeared, recipient corneal epithelial cells grew collagen type III stromal content, corneal rigidity and stromal haze decreased, stromal ultrastructure was restored, and vision was improved. Their work concluded that corneal stromal stem cells could reverse the formation of mechanism scars and had the ability to promote the regeneration of transparent stromal tissue. Someone has investigated the mechanism and found that corneal stromal stem cells inhibited neutrophil infiltration on injured corneas by secreting TSG-6, thereby reversing scar formation[179].

**Corneal endothelial cells and cell progenitors**

***Anatomy***

Corneal endothelial cells (CECs) are important for maintaining corneal transparency. The corneal endothelium is derived from the neural crest and forms a monolayer of hexagonal cells[180]. In the past, the corneal endothelium has been thought to be different from the corneal epithelium in that once the mature single-cell layer is formed, corneal endothelial cells lose their ability to proliferate. Instead of regenerating into new cells to replace dead or damaged cells, the wound can only be repaired by the expansion and migration of endothelial cells around the damaged area, resulting in a decrease in the density of endothelial cells by 0.3%-0.6% per year[181].

However, corneal endothelial cell progenitors, similar in part to stem cells, have been found to have the ability to self-renew and differentiate into mature effector cells. The progenitors are thought to be situated in the posterior limbus, a transitional area (also known as Schwalbe’s ring region) from the periphery of the endothelium and Schwalbe’s line to the anterior portion of the trabecular meshwork (TM). These hypothesized corneal endothelial cell precursors give rise to corneal endothelial cells and trabecular cells[5-7]. However, progenitor cells and stem cells are not exactly the same and cannot be substituted for each other. The self-renewal ability of progenitor cells is limited, which results in apoptosis of progenitors at the end of differentiation. Nevertheless, in contrast with the previous view that corneal endothelial cells cannot proliferate at all, the discovery of corneal endothelial progenitor cells has profound implications.

***Characteristics***

**Different cell densities:** The density distribution of corneal endothelial cells is uneven. B H Schimmelpfennig divided the collected corneas into two groups for staining. He found that in both 19 corneas stained with Orcein and 22 corneas stained with Alizarin Red, the cell density of the peripheral corneal endothelium was approximately 23.5% higher than that of the central corneal endothelium[182,183]. This difference in density suggests that the smaller peripheral endothelial cells can migrate to the centre by increasing the area, which is conducive to the repair of the corneal endothelium. Meanwhile, the possibility that progenitor cells may exist in the peripheral transition region to provide differentiated endothelial cells is also suggested[5].

**The proliferative ability is related to the location:** Several studies have demonstrated that the proliferative ability of peripheral endothelial cells is stronger than that of central corneal cells in terms of cell distribution, molecular expression, senescence status and mitotic activity[183-186]. In 2000, Senoo *et al*[187] found that corneal endothelial cells can enter and complete the cell cycle *in vitro* after corneal endothelial injury, regardless of donor age. However, corneal endothelial cells from older donors responded more slowly and to a lesser extent than cells from younger donors. Subsequently, Mimura *et al*[186] further investigated the replication capacity of human corneal endothelial cells (HCECs) in central and peripheral regions and between young and old donors. They divided the corneas into a younger group (donors younger than 30) and an older group (donors older than 50). Minichromosome maintenance (MCM)-2 (a marker of replication competence) and senescence-associated β-galactosidase activity (SA-β-Gal) (a marker for identifying senescent HCECs) were used for staining. They found that in corneas from elderly donors, significantly fewer HCECs migrated to the central wound than to the periphery. Compared with HCECs from the young group with little SA-β-Gal activity both in the central or peripheral regions, the SA-β-Gal activity of HCECs from the older group was easier to detect, and the SA-β-Gal activity of central HCECs was significantly higher than that of peripheral HCECs. In both the younger and older groups, there were more MCM-2-positive cells in the peripheral corneal injury area than in the central corneal injury area. *In vitro*, HCECs from the peripheral region can be shown to have a higher replication capacity than HCECs from the central region, regardless of donor age. Therefore, the peripheral cornea has been suggested to act as a physiological supply and store for corneal endothelial cells so that the central cornea can be continuously supplied[183].

**Proliferation ability is related to age differences among donors:** After counting the stained proliferation marker protein Ki67, Senoo *et al*[187] found that the number and peak value of Ki67-labelled cells in the old group were significantly lower than that in the young group, and the speed of the old group entering the cell proliferation cycle was significantly slower than the speed in the young group. After *in vitro* culture and staining for Ki67 count, Zhu *et al*[188] found that the density of cells with positive staining in the young group was twice as high as that in the old group, and the time required for them to enter the cell cycle was half as long as that in the old group; Konomi *et al*[189] found that the doubling time tended to be higher for cells from older donors. Some people proposed explanations for these findings. Joyce[190] believed that with increasing age, the number of corneal endothelial cells entering the proliferative and senile phases gradually increased, and the expression of CKIS also increased, leading to a decrease in cell proliferation activity and a significantly reduced response to mitotic agents. In addition, Joyce *et al*[191] found that increased concentrations of 8-hydroxy-2’-deoxyguanosine (8-OHDG), a cell oxidative stress product, resulted in decreased proliferation.

As a result, the density and proliferation of peripheral endothelial cells are higher than those of central endothelial cells, although the proliferation of endothelial cells decreases with age. This conclusion strongly suggests that there may be corneal endothelial cell progenitors in the periphery of endothelial cells (namely Schwalbe’s ring).

***Molecular markers for corneal endothelial cell progenitors***

As early as 2005, Whikehart *et al*[192] detected telomerase activity (a stem cell marker) in the peripheral cornea, and bromodeoxyuridine (BrdU), a marker of cell division, was observed in the trabecular meshwork (TM) and the posterior limbus. After mechanical injury to the corneal endothelium, BrdU fusion was increased and extended to the corneal endothelium. In 2007, McGowan *et al*[193] found that cells from Schwalbe’s Ring expressed stem cell markers (Nestin, alkaline phosphatase, and telomerase). Additional putative stem cell markers (OCT3/4, Wnt1) and differentiation markers (Pax6, Sox2) were observed after corneal injury. In 2019, Yam *et al*[194] found that the cells expressing progenitor cell markers (*i.e.*, SOX2, Lgr5, CD34, Pitx2 and telomerase) were involved in Schwalbe’s Ring on the side of the corneal endothelium. In addition, many studies have found that corneal endothelial progenitors express p75NTR, SOX9, FOXC2, Twist, Snail, and Slug[195,196].

***Transplantation and therapeutic potential***

Corneal endothelial cells play an important role in maintaining the stability and transparency of the corneal environment. When obvious visual impairment causes irreversible damage, the best strategy is to replace it with allogeneic corneal endothelial cells. However, severe rejection and a global shortage of donor corneal tissue have led people to seek alternative sources of transplantable tissue. Parikumar *et al*[197,198] successfully used a transparent nanocomposite sheet to transplant donor human corneal and colorectal cells into a cow’s eye, and implanted HCECs within three hours after transplantation. Their experiment paved the way for further clinical research.

On the basis of previous studies, Frausto *et al*[199] used next-generation RNA sequencing technology to compare human corneal endothelial cells (evHCEnCs) cultured *in vitro* with primary human corneal endothelial cells (pHCEnCs) and the human corneal endothelial cell (HCEnC) transcription profile. Transcriptomics analysis shows that at the molecular level, pHCEnCs are the most similar to evHCEnCs and therefore represent the most feasible cell culture treatment for corneal endothelial cell dysfunction.

In addition, some studies have found that cells from other tissues may also be the source of CEC-like cells used to treat corneal endothelial diseases. Inagaki *et al*[200] successfully induced corneal endothelial cells from human skin-derived precursors (SKPs) and showed that the transplanted cornea also maintained the transparency and thickness of the cornea. Shen *et al*[201] obtained abundant CEC-like cells through the coculture of human SKPs and B4G12 cells. Similar to human CECs in morphology and characteristics, when CEC-like cells are transplanted into rabbit and monkey models of corneal endothelial dysfunction, they show excellent therapeutic effects. Shao *et al*[202] transformed human foetal bone marrow-derived colorectal progenitor cells (BEPCs) into corneal endothelial cells *in vitro*, which may be useful for repairing corneal endothelial dysfunction. Zhang *et al*[203] induced the differentiation of hESCs into periocular mesenchymal precursors (POMPs). Using lens epithelial cell conditioned medium, CEC-like cells were obtained from POMPs and successfully transplanted into the eyes of a rabbit CE dysfunction model to gradually restore corneal transparency. Chen *et al*[204] used a simpler method to generate HCEC-like cells from hESCs. This method can greatly reduce the production work of HCEC and has potential clinical application value.

**CONCLUSION**

In this review, we introduced the characteristics of corneal epithelial stem cells, corneal endothelial cell progenitors and corneal stromal stem cells in detail, identified their anatomical features of their location near the limbus of the cornea, discussed a variety of isolation and culture techniques and related molecular markers and summarized their application and potential in treatment (especially the treatment of LSCD). Research on corneal stem cells is of great value for corneal transplantation, regenerative medicine and bioengineered corneal grafts, especially in the era of scarce corneal donors, which will bring good news to patients with corneal diseases worldwide.

**REFERENCES**

1 **Rüfer F**, Schröder A, Erb C. White-to-white corneal diameter: normal values in healthy humans obtained with the Orbscan II topography system. *Cornea* 2005; **24**: 259-261 [PMID: 15778595 DOI: 10.1097/01.ico.0000148312.01805.53]

2 **Fares U**, Otri AM, Al-Aqaba MA, Dua HS. Correlation of central and peripheral corneal thickness in healthy corneas. *Cont Lens Anterior Eye* 2012; **35**: 39-45 [PMID: 21885326 DOI: 10.1016/j.clae.2011.07.004]

3 **DelMonte DW**, Kim T. Anatomy and physiology of the cornea. *J Cataract Refract Surg* 2011; **37**: 588-598 [PMID: 21333881 DOI: 10.1016/j.jcrs.2010.12.037]

4 **Schlötzer-Schrehardt U**, Kruse FE. Identification and characterization of limbal stem cells. *Exp Eye Res* 2005; **81**: 247-264 [PMID: 16051216 DOI: 10.1016/j.exer.2005.02.016]

5 **Yu WY**, Sheridan C, Grierson I, Mason S, Kearns V, Lo AC, Wong D. Progenitors for the corneal endothelium and trabecular meshwork: a potential source for personalized stem cell therapy in corneal endothelial diseases and glaucoma. *J Biomed Biotechnol* 2011; **2011**: 412743 [PMID: 22187525 DOI: 10.1155/2011/412743]

6 **Meir YJ**, Chen HC, Chen CC, Ma HD. Revisiting Existing Evidence of Corneal Endothelial Progenitors and Their Potential Therapeutic Applications in Corneal Endothelial Dysfunction. *Adv Ther* 2020; **37**: 1034-1048 [PMID: 32002810 DOI: 10.1007/s12325-020-01237-w]

7 **Liu Y**, Sun H, Guo P, Hu M, Zhang Y, Tighe S, Chen S, Zhu Y. Characterization and Prospective of Human Corneal Endothelial Progenitors. *Int J Med Sci* 2017; **14**: 705-710 [PMID: 28824304 DOI: 10.7150/ijms.19018]

8 **Wolosin JM**, Budak MT, Akinci MA. Ocular surface epithelial and stem cell development. *Int J Dev Biol* 2004; **48**: 981-991 [PMID: 15558489 DOI: 10.1387/ijdb.041876jw]

9 **Du Y**, Funderburgh ML, Mann MM, SundarRaj N, Funderburgh JL. Multipotent stem cells in human corneal stroma. *Stem Cells* 2005; **23**: 1266-1275 [PMID: 16051989 DOI: 10.1634/stemcells.2004-0256]

10 **Li DQ**, Wang Z, Yoon KC, Bian F. Characterization, isolation, expansion and clinical therapy of human corneal epithelial stem/progenitor cells. *J Stem Cells* 2014; **9**: 79-91 [PMID: 25158157]

11 **Van Buskirk EM**. The anatomy of the limbus. *Eye (Lond)* 1989; **3 ( Pt 2)**: 101-108 [PMID: 2695343 DOI: 10.1038/eye.1989.16]

12 **Kenyon KR**, Tseng SC. Limbal autograft transplantation for ocular surface disorders. *Ophthalmology* 1989; **96**: 709-22; discussion 722-3 [PMID: 2748125 DOI: 10.1016/s0161-6420(89)32833-8]

13 **Li W**, Hayashida Y, Chen YT, Tseng SC. Niche regulation of corneal epithelial stem cells at the limbus. *Cell Res* 2007; **17**: 26-36 [PMID: 17211449 DOI: 10.1038/sj.cr.7310137]

14 **Nurković JS**, Vojinović R, Dolićanin Z. Corneal Stem Cells as a Source of Regenerative Cell-Based Therapy. *Stem Cells Int* 2020; **2020**: 8813447 [PMID: 32765614 DOI: 10.1155/2020/8813447]

15 **Gonzalez G**, Sasamoto Y, Ksander BR, Frank MH, Frank NY. Limbal stem cells: identity, developmental origin, and therapeutic potential. *Wiley Interdiscip Rev Dev Biol* 2018; **7** [PMID: 29105366 DOI: 10.1002/wdev.303]

16 **Thoft RA**, Friend J. The X, Y, Z hypothesis of corneal epithelial maintenance. *Invest Ophthalmol Vis Sci* 1983; **24**: 1442-1443 [PMID: 6618809]

17 **Yoon JJ**, Ismail S, Sherwin T. Limbal stem cells: Central concepts of corneal epithelial homeostasis. *World J Stem Cells* 2014; **6**: 391-403 [PMID: 25258661 DOI: 10.4252/wjsc.v6.i4.391]

18 **Chang CY**, Green CR, McGhee CN, Sherwin T. Acute wound healing in the human central corneal epithelium appears to be independent of limbal stem cell influence. *Invest Ophthalmol Vis Sci* 2008; **49**: 5279-5286 [PMID: 18515566 DOI: 10.1167/iovs.07-1260]

19 **Schermer A**, Galvin S, Sun TT. Differentiation-related expression of a major 64K corneal keratin in vivo and in culture suggests limbal location of corneal epithelial stem cells. *J Cell Biol* 1986; **103**: 49-62 [PMID: 2424919 DOI: 10.1083/jcb.103.1.49]

20 **Kao WW**. Keratin expression by corneal and limbal stem cells during development. *Exp Eye Res* 2020; **200**: 108206 [PMID: 32882212 DOI: 10.1016/j.exer.2020.108206]

21 **Notara M**, Lentzsch A, Clahsen T, Behboudifard S, Braun G, Cursiefen C. Bevacizumab Induces Upregulation of Keratin 3 and VEGFA in Human Limbal Epithelial Cells in Vitro. *J Clin Med* 2019; **8** [PMID: 31717500 DOI: 10.3390/jcm8111925]

22 **Mei H**, Nakatsu MN, Baclagon ER, Deng SX. Frizzled 7 maintains the undifferentiated state of human limbal stem/progenitor cells. *Stem Cells* 2014; **32**: 938-945 [PMID: 24170316 DOI: 10.1002/stem.1582]

23 **Dua HS**, Azuara-Blanco A. Limbal stem cells of the corneal epithelium. *Surv Ophthalmol* 2000; **44**: 415-425 [PMID: 10734241 DOI: 10.1016/s0039-6257(00)00109-0]

24 **Sartaj R**, Zhang C, Wan P, Pasha Z, Guaiquil V, Liu A, Liu J, Luo Y, Fuchs E, Rosenblatt MI. Characterization of slow cycling corneal limbal epithelial cells identifies putative stem cell markers. *Sci Rep* 2017; **7**: 3793 [PMID: 28630424 DOI: 10.1038/s41598-017-04006-y]

25 **Pajoohesh-Ganji A**, Pal-Ghosh S, Simmens SJ, Stepp MA. Integrins in slow-cycling corneal epithelial cells at the limbus in the mouse. *Stem Cells* 2006; **24**: 1075-1086 [PMID: 16282441 DOI: 10.1634/stemcells.2005-0382]

26 **Mariappan I**, Kacham S, Purushotham J, Maddileti S, Siamwala J, Sangwan VS. Spatial distribution of niche and stem cells in *Ex vivo* human limbal cultures. *Stem Cells Transl Med* 2014; **3**: 1331-1341 [PMID: 25232182 DOI: 10.5966/sctm.2014-0120]

27 **Zhao J**, Mo V, Nagasaki T. Distribution of label-retaining cells in the limbal epithelium of a mouse eye. *J Histochem Cytochem* 2009; **57**: 177-185 [PMID: 19001638 DOI: 10.1369/jhc.2008.952390]

28 **Hernandez Galindo EE**, Theiss C, Steuhl KP, Meller D. Expression of Delta Np63 in response to phorbol ester in human limbal epithelial cells expanded on intact human amniotic membrane. *Invest Ophthalmol Vis Sci* 2003; **44**: 2959-2965 [PMID: 12824238 DOI: 10.1167/iovs.02-0776]

29 **Boroumand N**, Nosrati Tirkani A, Javid D, Hasani A, Taherzadeh D, Hosseinzadeh A, Nooripour S, Zarei-Ghanavati S, Hashemy SI, Alamdari DH. Novelty in limbal stem cell culture and cell senescence. *Exp Eye Res* 2019; **181**: 294-301 [PMID: 30807745 DOI: 10.1016/j.exer.2019.02.015]

30 **Hou L**, Fu W, Liu Y, Wang Q, Wang L, Huang Y. Agrin Promotes Limbal Stem Cell Proliferation and Corneal Wound Healing Through Hippo-Yap Signaling Pathway. *Invest Ophthalmol Vis Sci* 2020; **61**: 7 [PMID: 32392315 DOI: 10.1167/iovs.61.5.7]

31 **Puri S**, Sun M, Mutoji KN, Gesteira TF, Coulson-Thomas VJ. Epithelial Cell Migration and Proliferation Patterns During Initial Wound Closure in Normal Mice and an Experimental Model of Limbal Stem Cell Deficiency. *Invest Ophthalmol Vis Sci* 2020; **61**: 27 [PMID: 32790859 DOI: 10.1167/iovs.61.10.27]

32 **Ho TC**, Chen SL, Wu JY, Ho MY, Chen LJ, Hsieh JW, Cheng HC, Tsao YP. PEDF promotes self-renewal of limbal stem cell and accelerates corneal epithelial wound healing. *Stem Cells* 2013; **31**: 1775-1784 [PMID: 23553951 DOI: 10.1002/stem.1393]

33 **Sagga N**, Kuffová L, Vargesson N, Erskine L, Collinson JM. Limbal epithelial stem cell activity and corneal epithelial cell cycle parameters in adult and aging mice. *Stem Cell Res* 2018; **33**: 185-198 [PMID: 30439642 DOI: 10.1016/j.scr.2018.11.001]

34 **Ishii R**, Yanagisawa H, Sada A. Defining compartmentalized stem cell populations with distinct cell division dynamics in the ocular surface epithelium. *Development* 2020; **147** [PMID: 33199446 DOI: 10.1242/dev.197590]

35 **Hamam R**, Bhat P, Foster CS. Conjunctival/corneal intraepithelial neoplasia. *Int Ophthalmol Clin* 2009; **49**: 63-70 [PMID: 19125065 DOI: 10.1097/IIO.0b013e3181924ec3]

36 **Bonnay G**, Saleh M, Sauer A, Gaucher D, Speeg-Schatz C, Bourcier T. [Corneal intraepithelial neoplasia]. *J Fr Ophtalmol* 2012; **35**: 150-151 [PMID: 22243652 DOI: 10.1016/j.jfo.2011.03.020]

37 **Alomar TS**, Nubile M, Lowe J, Dua HS. Corneal intraepithelial neoplasia: in vivo confocal microscopic study with histopathologic correlation. *Am J Ophthalmol* 2011; **151**: 238-247 [PMID: 21168809 DOI: 10.1016/j.ajo.2010.08.035]

38 **Lamprecht J**. Mitosis in the corneal epithelium. A preliminary communication on the coexistence of differential and equivalent cell divisions. *Cell Biol Int Rep* 1987; **11**: 449-455 [PMID: 3621353 DOI: 10.1016/0309-1651(87)90078-6]

39 **Lamprecht J**. Symmetric and asymmetric cell division in rat corneal epithelium. *Cell Tissue Kinet* 1990; **23**: 203-216 [PMID: 2357719 DOI: 10.1111/j.1365-2184.1990.tb01116.x]

40 **Romano AC**, Espana EM, Yoo SH, Budak MT, Wolosin JM, Tseng SC. Different cell sizes in human limbal and central corneal basal epithelia measured by confocal microscopy and flow cytometry. *Invest Ophthalmol Vis Sci* 2003; **44**: 5125-5129 [PMID: 14638707 DOI: 10.1167/iovs.03-0628]

41 **Chen Z**, de Paiva CS, Luo L, Kretzer FL, Pflugfelder SC, Li DQ. Characterization of putative stem cell phenotype in human limbal epithelia. *Stem Cells* 2004; **22**: 355-366 [PMID: 15153612 DOI: 10.1634/stemcells.22-3-355]

42 **Yamamoto N**, Hirano K, Kojima H, Sumitomo M, Yamashita H, Ayaki M, Taniguchi K, Tanikawa A, Horiguchi M. Cultured human corneal epithelial stem/progenitor cells derived from the corneal limbus. *In Vitro Cell Dev Biol Anim* 2010; **46**: 774-780 [PMID: 20844981 DOI: 10.1007/s11626-010-9344-9]

43 **Shaharuddin B**, Harvey I, Ahmad S, Ali S, Meeson A. Characterisation of human limbal side population cells isolated using an optimised protocol from an immortalised epithelial cell line and primary limbal cultures. *Stem Cell Rev Rep* 2014; **10**: 240-250 [PMID: 24174130 DOI: 10.1007/s12015-013-9481-0]

44 **Nam E**, Takahashi A, Fujita N, Tsuzuki K, Nishimura R. Cultivation of corneal epithelial cell sheets on canine amniotic membrane. *Vet Ophthalmol* 2013; **16**: 263-268 [PMID: 23067315 DOI: 10.1111/j.1463-5224.2012.01070.x]

45 **Moriyama H**, Kasashima Y, Kuwano A, Wada S. Anatomical location and culture of equine corneal epithelial stem cells. *Vet Ophthalmol* 2014; **17**: 106-112 [PMID: 23710670 DOI: 10.1111/vop.12050]

46 **Nam E**, Fujita N, Morita M, Tsuzuki K, Lin HY, Chung CS, Nakagawa T, Nishimura R. Comparison of the canine corneal epithelial cell sheets cultivated from limbal stem cells on canine amniotic membrane, atelocollagen gel, and temperature-responsive culture dish. *Vet Ophthalmol* 2015; **18**: 317-325 [PMID: 25495909 DOI: 10.1111/vop.12241]

47 **Kim JC**, Tseng SC. Transplantation of preserved human amniotic membrane for surface reconstruction in severely damaged rabbit corneas. *Cornea* 1995; **14**: 473-484 [PMID: 8536460]

48 **Koizumi N**, Inatomi T, Suzuki T, Sotozono C, Kinoshita S. Cultivated corneal epithelial stem cell transplantation in ocular surface disorders. *Ophthalmology* 2001; **108**: 1569-1574 [PMID: 11535452 DOI: 10.1016/s0161-6420(01)00694-7]

49 **Basu S**, Ali H, Sangwan VS. Clinical outcomes of repeat autologous cultivated limbal epithelial transplantation for ocular surface burns. *Am J Ophthalmol* 2012; **153**: 643-650, 650.e1-650.e2 [PMID: 22265153 DOI: 10.1016/j.ajo.2011.09.016]

50 **Sangwan VS**, Basu S, Vemuganti GK, Sejpal K, Subramaniam SV, Bandyopadhyay S, Krishnaiah S, Gaddipati S, Tiwari S, Balasubramanian D. Clinical outcomes of xeno-free autologous cultivated limbal epithelial transplantation: a 10-year study. *Br J Ophthalmol* 2011; **95**: 1525-1529 [PMID: 21890785 DOI: 10.1136/bjophthalmol-2011-300352]

51 **Ramuta TŽ**, Šket T, Starčič Erjavec M, Kreft ME. Antimicrobial Activity of Human Fetal Membranes: From Biological Function to Clinical Use. *Front Bioeng Biotechnol* 2021; **9**: 691522 [PMID: 34136474 DOI: 10.3389/fbioe.2021.691522]

52 **Kesting MR**, Wolff KD, Nobis CP, Rohleder NH. Amniotic membrane in oral and maxillofacial surgery. *Oral Maxillofac Surg* 2014; **18**: 153-164 [PMID: 23242942 DOI: 10.1007/s10006-012-0382-1]

53 **Sharma N**, Mohanty S, Jhanji V, Vajpayee RB. Amniotic membrane transplantation with or without autologous cultivated limbal stem cell transplantation for the management of partial limbal stem cell deficiency. *Clin Ophthalmol* 2018; **12**: 2103-2106 [PMID: 30410305 DOI: 10.2147/OPTH.S181035]

54 **Meyer-Blazejewska EA**, Kruse FE, Bitterer K, Meyer C, Hofmann-Rummelt C, Wünsch PH, Schlötzer-Schrehardt U. Preservation of the limbal stem cell phenotype by appropriate culture techniques. *Invest Ophthalmol Vis Sci* 2010; **51**: 765-774 [PMID: 19710417 DOI: 10.1167/iovs.09-4109]

55 **Ghoubay-Benallaoua D**, Sandali O, Goldschmidt P, Borderie V. Kinetics of expansion of human limbal epithelial progenitor cells in primary culture of explants without feeders. *PLoS One* 2013; **8**: e81965 [PMID: 24312615 DOI: 10.1371/journal.pone.0081965]

56 **Zito-Abbad E**, Borderie VM, Baudrimont M, Bourcier T, Laroche L, Chapel C, Uzel JL. Corneal epithelial cultures generated from organ-cultured limbal tissue: factors influencing epithelial cell growth. *Curr Eye Res* 2006; **31**: 391-399 [PMID: 16714230 DOI: 10.1080/02713680600681228]

57 **Lekhanont K**, Choubtum L, Chuck RS, Sa-ngiampornpanit T, Chuckpaiwong V, Vongthongsri A. A serum- and feeder-free technique of culturing human corneal epithelial stem cells on amniotic membrane. *Mol Vis* 2009; **15**: 1294-1302 [PMID: 19578552]

58 **Tekkatte C**, Gunasingh GP, Cherian KM, Sankaranarayanan K. "Humanized" stem cell culture techniques: the animal serum controversy. *Stem Cells Int* 2011; **2011**: 504723 [PMID: 21603148 DOI: 10.4061/2011/504723]

59 **Yokoo S**, Yamagami S, Usui T, Amano S, Araie M. Human corneal epithelial equivalents for ocular surface reconstruction in a complete serum-free culture system without unknown factors. *Invest Ophthalmol Vis Sci* 2008; **49**: 2438-2443 [PMID: 18515584 DOI: 10.1167/iovs.06-1448]

60 **López-Paniagua M**, Nieto-Miguel T, de la Mata A, Dziasko M, Galindo S, Rey E, Herreras JM, Corrales RM, Daniels JT, Calonge M. Comparison of functional limbal epithelial stem cell isolation methods. *Exp Eye Res* 2016; **146**: 83-94 [PMID: 26704459 DOI: 10.1016/j.exer.2015.12.002]

61 **Shirzadeh E**, Heidari Keshel S, Ezzatizadeh V, Jabbehdari S, Baradaran-Rafii A. Unrestricted somatic stem cells, as a novel feeder layer: *Ex vivo* culture of human limbal stem cells. *J Cell Biochem* 2018; **119**: 2666-2678 [PMID: 29087592 DOI: 10.1002/jcb.26434]

62 **Li DQ**, Kim S, Li JM, Gao Q, Choi J, Bian F, Hu J, Zhang Y, Li J, Lu R, Li Y, Pflugfelder SC, Miao H, Chen R. Single-cell transcriptomics identifies limbal stem cell population and cell types mapping its differentiation trajectory in limbal basal epithelium of human cornea. *Ocul Surf* 2021; **20**: 20-32 [PMID: 33388438 DOI: 10.1016/j.jtos.2020.12.004]

63 **Williams KA**, Coster DJ. The immunobiology of corneal transplantation. *Transplantation* 2007; **84**: 806-813 [PMID: 17984831 DOI: 10.1097/01.tp.0000285489.91595.13]

64 **O'Sullivan F**, Clynes M. Limbal stem cells, a review of their identification and culture for clinical use. *Cytotechnology* 2007; **53**: 101-106 [PMID: 19003195 DOI: 10.1007/s10616-007-9063-6]

65 **Nover A**, Hochgesand P. [Diseases of the anterior segment of the eye. Diagnosis and therapy-3. Cornea, sclera, iris, injuries]. *Fortschr Med* 1974; **92**: 321-324 [PMID: 4818257]

66 **Arpitha P**, Prajna NV, Srinivasan M, Muthukkaruppan V. High expression of p63 combined with a large N/C ratio defines a subset of human limbal epithelial cells: implications on epithelial stem cells. *Invest Ophthalmol Vis Sci* 2005; **46**: 3631-3636 [PMID: 16186343 DOI: 10.1167/iovs.05-0343]

67 **Lyngholm M**, Vorum H, Nielsen K, Østergaard M, Honoré B, Ehlers N. Differences in the protein expression in limbal versus central human corneal epithelium--a search for stem cell markers. *Exp Eye Res* 2008; **87**: 96-105 [PMID: 18571161 DOI: 10.1016/j.exer.2008.05.001]

68 **Nelson KK**, Melendez JA. Mitochondrial redox control of matrix metalloproteinases. *Free Radic Biol Med* 2004; **37**: 768-784 [PMID: 15304253 DOI: 10.1016/j.freeradbiomed.2004.06.008]

69 **Thomas PB**, Liu YH, Zhuang FF, Selvam S, Song SW, Smith RE, Trousdale MD, Yiu SC. Identification of Notch-1 expression in the limbal basal epithelium. *Mol Vis* 2007; **13**: 337-344 [PMID: 17392684]

70 **Budak MT**, Alpdogan OS, Zhou M, Lavker RM, Akinci MA, Wolosin JM. Ocular surface epithelia contain ABCG2-dependent side population cells exhibiting features associated with stem cells. *J Cell Sci* 2005; **118**: 1715-1724 [PMID: 15811951 DOI: 10.1242/jcs.02279]

71 **Naranjo Gómez JM**, Bernal JF, Arranz PG, Fernández SL, Roman JJ. Alterations in the expression of p53, KLF4, and p21 in neuroendocrine lung tumors. *Arch Pathol Lab Med* 2014; **138**: 936-942 [PMID: 24978920 DOI: 10.5858/arpa.2013-0119-OA]

72 **Fujimoto S**, Hayashi R, Hara S, Sasamoto Y, Harrington J, Tsujikawa M, Nishida K. KLF4 prevents epithelial to mesenchymal transition in human corneal epithelial cells *via* endogenous TGF-β2 suppression. *Regen Ther* 2019; **11**: 249-257 [PMID: 31538102 DOI: 10.1016/j.reth.2019.08.003]

73 **Akin D**, Newman JR, McIntyre LM, Sugrue SP. RNA-seq analysis of impact of PNN on gene expression and alternative splicing in corneal epithelial cells. *Mol Vis* 2016; **22**: 40-60 [PMID: 26900324]

74 **Tseng SC**. Concept and application of limbal stem cells. *Eye (Lond)* 1989; **3 ( Pt 2)**: 141-157 [PMID: 2695347 DOI: 10.1038/eye.1989.22]

75 **Le Q**, Xu J, Deng SX. The diagnosis of limbal stem cell deficiency. *Ocul Surf* 2018; **16**: 58-69 [PMID: 29113917 DOI: 10.1016/j.jtos.2017.11.002]

76 **Sejpal K**, Bakhtiari P, Deng SX. Presentation, diagnosis and management of limbal stem cell deficiency. *Middle East Afr J Ophthalmol* 2013; **20**: 5-10 [PMID: 23580847 DOI: 10.4103/0974-9233.106381]

77 **Ihnatko R**, Eden U, Fagerholm P, Lagali N. Congenital Aniridia and the Ocular Surface. *Ocul Surf* 2016; **14**: 196-206 [PMID: 26738798 DOI: 10.1016/j.jtos.2015.10.003]

78 **Vazirani J**, Nair D, Shanbhag S, Wurity S, Ranjan A, Sangwan V. Limbal Stem Cell Deficiency-Demography and Underlying Causes. *Am J Ophthalmol* 2018; **188**: 99-103 [PMID: 29378178 DOI: 10.1016/j.ajo.2018.01.020]

79 **Cartes C**, Lako M, Figueiredo FC. Referral Patterns of Patients with Limbal Stem Cell Deficiency to a Specialized Tertiary Center in the United Kingdom. *Ophthalmol Ther* 2021; **10**: 535-545 [PMID: 34002332 DOI: 10.1007/s40123-021-00349-y]

80 **Komoto S**, Oie Y, Kawasaki S, Kawasaki R, Nishida N, Soma T, Koh S, Maruyama K, Usui S, Matsushita K, Tsujikawa M, Maeda N, Nishida K. Quantitative Analysis of the Association Between Follow-Up Duration and Severity of Limbal Stem Cell Deficiency or Visual Acuity in Aniridia. *Invest Ophthalmol Vis Sci* 2020; **61**: 57 [PMID: 32589199 DOI: 10.1167/iovs.61.6.57]

81 **Lagali N**, Wowra B, Dobrowolski D, Utheim TP, Fagerholm P, Wylegala E. Stage-related central corneal epithelial transformation in congenital aniridia-associated keratopathy. *Ocul Surf* 2018; **16**: 163-172 [PMID: 29133179 DOI: 10.1016/j.jtos.2017.11.003]

82 **Srirampur A**, Mansoori T, Rebbala P. Zinsser-Engman-Cole Syndrome Presenting as Partial Limbal Stem Cell Deficiency. *Cureus* 2020; **12**: e10933 [PMID: 33194499 DOI: 10.7759/cureus.10933]

83 **Ruan Y**, Jiang S, Musayeva A, Pfeiffer N, Gericke A. Corneal Epithelial Stem Cells-Physiology, Pathophysiology and Therapeutic Options. *Cells* 2021; **10** [PMID: 34571952 DOI: 10.3390/cells10092302]

84 **Iyer G**, Srinivasan B, Dhiman R, Agarwal M, Rajagopal R. Preliminary experience & rationale of primary allo Simple Limbal Epithelial Transplantation (SLET) following surgical excision of Ocular Surface Tumors. *Ocul Surf* 2021; **22**: 120-122 [PMID: 34352364 DOI: 10.1016/j.jtos.2021.07.007]

85 **Diel H**, Ding C, Grehn F, Chronopoulos P, Bartsch O, Hoffmann EM. First observation of secondary childhood glaucoma in Coffin-Siris syndrome: a case report and literature review. *BMC Ophthalmol* 2021; **21**: 28 [PMID: 33430815 DOI: 10.1186/s12886-020-01788-0]

86 **Cheung AY**, Patel S, Kurji KH, Sarnicola E, Eslani M, Govil A, Holland EJ. Ocular Surface Stem Cell Transplantation for Treatment of Keratitis-Ichthyosis-Deafness Syndrome. *Cornea* 2019; **38**: 123-126 [PMID: 30371567 DOI: 10.1097/ICO.0000000000001802]

87 **Thanos M**, Pauklin M, Steuhl KP, Meller D. Ocular surface reconstruction with cultivated limbal epithelium in a patient with unilateral stem cell deficiency caused by Epidermolysis bullosa dystrophica hallopeau-Siemens. *Cornea* 2010; **29**: 462-464 [PMID: 20164760 DOI: 10.1097/ICO.0b013e3181b442ea]

88 **Panthier C**, Bouvet M, Debellemaniere G, Gatinel D. Conjunctival limbal autografting (CLAU) combined with customised simple limbal epithelial transplantation (SLET) in a severe corneal chemical burn: Case report. *Am J Ophthalmol Case Rep* 2020; **20**: 100906 [PMID: 32984648 DOI: 10.1016/j.ajoc.2020.100906]

89 **Kethiri AR**, Raju E, Bokara KK, Mishra DK, Basu S, Rao CM, Sangwan VS, Singh V. Inflammation, vascularization and goblet cell differences in LSCD: Validating animal models of corneal alkali burns. *Exp Eye Res* 2019; **185**: 107665 [PMID: 31095932 DOI: 10.1016/j.exer.2019.05.005]

90 **Arya SK**, Bhatti A, Raj A, Bamotra RK. Simple Limbal Epithelial Transplantation in Acid Injury and Severe Dry Eye. *J Clin Diagn Res* 2016; **10**: ND06-ND07 [PMID: 27504323 DOI: 10.7860/JCDR/2016/19306.7997]

91 **Ray Chaudhuri B**, Bhaduri A, Sengupta M. The ocular surface after simple limbal epithelial transplant (SLET): A high-resolution OCT study of the early postoperative period. *Indian J Ophthalmol* 2019; **67**: 1348-1350 [PMID: 31332139 DOI: 10.4103/ijo.IJO\_1722\_18]

92 **Yin J**, Jurkunas U. Limbal Stem Cell Transplantation and Complications. *Semin Ophthalmol* 2018; **33**: 134-141 [PMID: 29172876 DOI: 10.1080/08820538.2017.1353834]

93 **Afsharkhamseh N**, Movahedan A, Gidfar S, Huvard M, Wasielewski L, Milani BY, Eslani M, Djalilian AR. Stability of limbal stem cell deficiency after mechanical and thermal injuries in mice. *Exp Eye Res* 2016; **145**: 88-92 [PMID: 26607808 DOI: 10.1016/j.exer.2015.11.012]

94 **Ting DSJ**, Rana-Rahman R, Ng JY, Wilkinson DJP, Ah-Kine D, Patel T. Clinical Spectrum and Outcomes of Ocular and Periocular Complications following External-Beam Radiotherapy for Inoperable Malignant Maxillary Sinus Tumors. *Ocul Oncol Pathol* 2021; **7**: 36-43 [PMID: 33796515 DOI: 10.1159/000511011]

95 **Carreno-Galeano JT**, Dohlman TH, Yin J, Dana R. Limbal Stem Cell Deficiency Associated With Herpes Keratitis. *Cornea* 2021; **40**: 967-971 [PMID: 33009093 DOI: 10.1097/ICO.0000000000002557]

96 **Donisi PM**, Rama P, Fasolo A, Ponzin D. Analysis of limbal stem cell deficiency by corneal impression cytology. *Cornea* 2003; **22**: 533-538 [PMID: 12883346 DOI: 10.1097/00003226-200308000-00009]

97 **Dawson CR**, Juster R, Marx R, Daghfous MT, Ben Djerad A. Limbal disease in trachoma and other ocular chlamydial infections: risk factors for corneal vascularisation. *Eye (Lond)* 1989; **3 ( Pt 2)**: 204-209 [PMID: 2620749 DOI: 10.1038/eye.1989.29]

98 **Dua HS**, Azuara-Blanco A. Allo-limbal transplantation in patients with limbal stem cell deficiency. *Br J Ophthalmol* 1999; **83**: 414-419 [PMID: 10434862 DOI: 10.1136/bjo.83.4.414]

99 **Lyall DA**, Srinivasan S, Roberts F. Limbal stem cell failure secondary to advanced conjunctival squamous cell carcinoma: a clinicopathological case report. *BMJ Case Rep* 2009; **2009** [PMID: 22121391 DOI: 10.1136/bcr.09.2009.2272]

100 **Tosi GM**, Traversi C, Schuerfeld K, Mittica V, Massaro-Giordano M, Tilanus MA, Caporossi A, Toti P. Amniotic membrane graft: histopathological findings in five cases. *J Cell Physiol* 2005; **202**: 852-857 [PMID: 15481059 DOI: 10.1002/jcp.20180]

101 **Lichtinger A**, Pe'er J, Frucht-Pery J, Solomon A. Limbal stem cell deficiency after topical mitomycin C therapy for primary acquired melanosis with atypia. *Ophthalmology* 2010; **117**: 431-437 [PMID: 20060167 DOI: 10.1016/j.ophtha.2009.07.032]

102 **Lin Z**, He H, Zhou T, Liu X, Wang Y, He H, Wu H, Liu Z. A mouse model of limbal stem cell deficiency induced by topical medication with the preservative benzalkonium chloride. *Invest Ophthalmol Vis Sci* 2013; **54**: 6314-6325 [PMID: 23963168 DOI: 10.1167/iovs.12-10725]

103 **Muthusamy K**, Tuft SJ. Iatrogenic limbal stem cell deficiency following drainage surgery for glaucoma. *Can J Ophthalmol* 2018; **53**: 574-579 [PMID: 30502980 DOI: 10.1016/j.jcjo.2018.01.037]

104 **Sun Y**, Yung M, Huang L, Tseng C, Deng SX. Limbal Stem Cell Deficiency After Glaucoma Surgery. *Cornea* 2020; **39**: 566-572 [PMID: 31977730 DOI: 10.1097/ICO.0000000000002249]

105 **Rossen J**, Amram A, Milani B, Park D, Harthan J, Joslin C, McMahon T, Djalilian A. Contact Lens-induced Limbal Stem Cell Deficiency. *Ocul Surf* 2016; **14**: 419-434 [PMID: 27480488 DOI: 10.1016/j.jtos.2016.06.003]

106 **Lee SC**, Hyon JY, Jeon HS. Contact Lens Induced Limbal Stem Cell Deficiency: Clinical Features in Korean Patients. *Korean J Ophthalmol* 2019; **33**: 500-505 [PMID: 31833246 DOI: 10.3341/kjo.2019.0095]

107 **Paris Fdos S**, Gonçalves ED, Barros Jde N, Campos MS, Sato EH, Gomes JA. Impression cytology findings in bullous keratopathy. *Br J Ophthalmol* 2010; **94**: 773-776 [PMID: 19965819 DOI: 10.1136/bjo.2009.158881]

108 **Ma KN**, Thanos A, Chodosh J, Shah AS, Mantagos IS. A Novel Technique for Amniotic Membrane Transplantation in Patients with Acute Stevens-Johnson Syndrome. *Ocul Surf* 2016; **14**: 31-36 [PMID: 26387869 DOI: 10.1016/j.jtos.2015.07.002]

109 **Cheung AY**, Sarnicola E, Denny MR, Sepsakos L, Auteri NJ, Holland EJ. Limbal Stem Cell Deficiency: Demographics and Clinical Characteristics of a Large Retrospective Series at a Single Tertiary Referral Center. *Cornea* 2021; **40**: 1525-1531 [PMID: 34050070 DOI: 10.1097/ICO.0000000000002770]

110 **Sotozono C**, Inatomi T, Nakamura T, Koizumi N, Yokoi N, Ueta M, Matsuyama K, Kaneda H, Fukushima M, Kinoshita S. Cultivated oral mucosal epithelial transplantation for persistent epithelial defect in severe ocular surface diseases with acute inflammatory activity. *Acta Ophthalmol* 2014; **92**: e447-e453 [PMID: 24835597 DOI: 10.1111/aos.12397]

111 **Singh A**, Murthy SI, Gandhi A, Sangwan VS. "Doughnut" Amniotic Membrane Transplantation With Penetrating Keratoplasty for Vernal Keratoconjunctivitis With Limbal Stem Cell Disease. *Cornea* 2021; **40**: 914-916 [PMID: 33214419 DOI: 10.1097/ICO.0000000000002553]

112 **Donthineni PR**, Varma S, Kethiri A, Shanbhag S, Mishra DK, Singh V, Basu S. Histopathological Characteristics of Limbal Stem Cell Deficiency Secondary to Chronic Vernal Keratoconjunctivitis. *Cornea* 2022; **41**: 722-728 [PMID: 34116542 DOI: 10.1097/ICO.0000000000002775]

113 **Jabbehdari S**, Starnes TW, Kurji KH, Eslani M, Cortina MS, Holland EJ, Djalilian AR. Management of advanced ocular surface disease in patients with severe atopic keratoconjunctivitis. *Ocul Surf* 2019; **17**: 303-309 [PMID: 30528292 DOI: 10.1016/j.jtos.2018.12.002]

114 **Sinha S**, Singh RB, Dohlman TH, Wang M, Taketani Y, Yin J, Dana R. Prevalence of Persistent Corneal Epithelial Defects in Chronic Ocular Graft-Versus-Host Disease. *Am J Ophthalmol* 2020; **218**: 296-303 [PMID: 32717268 DOI: 10.1016/j.ajo.2020.05.035]

115 **Sivaraman KR**, Jivrajka RV, Soin K, Bouchard CS, Movahedan A, Shorter E, Jain S, Jacobs DS, Djalilian AR. Superior Limbic Keratoconjunctivitis-like Inflammation in Patients with Chronic Graft-Versus-Host Disease. *Ocul Surf* 2016; **14**: 393-400 [PMID: 27179980 DOI: 10.1016/j.jtos.2016.04.003]

116 **Deng SX**, Borderie V, Chan CC, Dana R, Figueiredo FC, Gomes JAP, Pellegrini G, Shimmura S, Kruse FE; and The International Limbal Stem Cell Deficiency Working Group. Global Consensus on Definition, Classification, Diagnosis, and Staging of Limbal Stem Cell Deficiency. *Cornea* 2019; **38**: 364-375 [PMID: 30614902 DOI: 10.1097/ICO.0000000000001820]

117 **Haagdorens M**, Van Acker SI, Van Gerwen V, Ní Dhubhghaill S, Koppen C, Tassignon MJ, Zakaria N. Limbal Stem Cell Deficiency: Current Treatment Options and Emerging Therapies. *Stem Cells Int* 2016; **2016**: 9798374 [PMID: 26788074 DOI: 10.1155/2016/9798374]

118 **Yeh SI**, Chu TW, Cheng HC, Wu CH, Tsao YP. The Use of Autologous Serum to Reverse Severe Contact Lens-induced Limbal Stem Cell Deficiency. *Cornea* 2020; **39**: 736-741 [PMID: 31985518 DOI: 10.1097/ICO.0000000000002264]

119 **Di Girolamo N**, Bosch M, Zamora K, Coroneo MT, Wakefield D, Watson SL. A contact lens-based technique for expansion and transplantation of autologous epithelial progenitors for ocular surface reconstruction. *Transplantation* 2009; **87**: 1571-1578 [PMID: 19461496 DOI: 10.1097/TP.0b013e3181a4bbf2]

120 **Dua HS**. The conjunctiva in corneal epithelial wound healing. *Br J Ophthalmol* 1998; **82**: 1407-1411 [PMID: 9930272 DOI: 10.1136/bjo.82.12.1407]

121 **Sabater AL**, Perez VL. Amniotic membrane use for management of corneal limbal stem cell deficiency. *Curr Opin Ophthalmol* 2017; **28**: 363-369 [PMID: 28426442 DOI: 10.1097/ICU.0000000000000386]

122 **Sacchetti M**, Rama P, Bruscolini A, Lambiase A. Limbal Stem Cell Transplantation: Clinical Results, Limits, and Perspectives. *Stem Cells Int* 2018; **2018**: 8086269 [PMID: 30405723 DOI: 10.1155/2018/8086269]

123 **Westekemper H**, Figueiredo FC, Siah WF, Wagner N, Steuhl KP, Meller D. Clinical outcomes of amniotic membrane transplantation in the management of acute ocular chemical injury. *Br J Ophthalmol* 2017; **101**: 103-107 [PMID: 27150827 DOI: 10.1136/bjophthalmol-2015-308037]

124 **Ozer MD**, Altinkurt E, Alparslan N. The long-term surgical outcomes of conjunctival-limbal autograft procedure with or without penetrating keratoplasty in eyes with unilateral limbal stem cell deficiency. *Taiwan J Ophthalmol* 2020; **10**: 22-28 [PMID: 32309120 DOI: 10.4103/tjo.tjo\_55\_19]

125 **Cheung AY**, Sarnicola E, Holland EJ. Long-Term Ocular Surface Stability in Conjunctival Limbal Autograft Donor Eyes. *Cornea* 2017; **36**: 1031-1035 [PMID: 28644241 DOI: 10.1097/ICO.0000000000001260]

126 **Kreimei M**, Sorkin N, Einan-Lifshitz A, Rootman DS, Chan CC. Long-term outcomes of donor eyes after conjunctival limbal autograft and allograft harvesting. *Can J Ophthalmol* 2019; **54**: 565-569 [PMID: 31564346 DOI: 10.1016/j.jcjo.2018.11.003]

127 **Ozer MD**, Altınkurt E, Yilmaz YC, Gedik AC, Alparslan N. The Surgical Outcomes of Limbal Allograft Transplantation in Eyes Having Limbal Stem Cell Deficiency. *J Curr Ophthalmol* 2020; **32**: 132-141 [PMID: 32775793 DOI: 10.4103/JOCO.JOCO\_91\_20]

128 **Krysik K**, Dobrowolski D, Tarnawska D, Wylegala E, Lyssek-Boroń A. Long-Term Outcomes of Allogeneic Ocular Surface Reconstruction: Keratolimbal Allograft (KLAL) Followed by Penetrating Keratoplasty (PK). *J Ophthalmol* 2020; **2020**: 5189179 [PMID: 32351724 DOI: 10.1155/2020/5189179]

129 **Behaegel J**, Zakaria N, Tassignon MJ, Leysen I, Bock F, Koppen C, Ní Dhubhghaill S. Short- and Long-Term Results of Xenogeneic-Free Cultivated Autologous and Allogeneic Limbal Epithelial Stem Cell Transplantations. *Cornea* 2019; **38**: 1543-1549 [PMID: 31569145 DOI: 10.1097/ICO.0000000000002153]

130 **Figueiredo GS**, Salvador-Culla B, Baylis OJ, Mudhar HS, Lako M, Figueiredo FC. Outcomes of Penetrating Keratoplasty Following Autologous Cultivated Limbal Epithelial Stem Cell Transplantation. *Stem Cells* 2018; **36**: 925-931 [PMID: 29436059 DOI: 10.1002/stem.2803]

131 **Jackson CJ**, Myklebust Ernø IT, Ringstad H, Tønseth KA, Dartt DA, Utheim TP. Simple limbal epithelial transplantation: Current status and future perspectives. *Stem Cells Transl Med* 2020; **9**: 316-327 [PMID: 31802651 DOI: 10.1002/sctm.19-0203]

132 **Shanbhag SS**, Nikpoor N, Rao Donthineni P, Singh V, Chodosh J, Basu S. Autologous limbal stem cell transplantation: a systematic review of clinical outcomes with different surgical techniques. *Br J Ophthalmol* 2020; **104**: 247-253 [PMID: 31118185 DOI: 10.1136/bjophthalmol-2019-314081]

133 **Basu S**, Mohan S, Bhalekar S, Singh V, Sangwan V. Simple limbal epithelial transplantation (SLET) in failed cultivated limbal epithelial transplantation (CLET) for unilateral chronic ocular burns. *Br J Ophthalmol* 2018; **102**: 1640-1645 [PMID: 29453224 DOI: 10.1136/bjophthalmol-2017-311506]

134 **Zhao Y**, Ma L. Systematic review and meta-analysis on transplantation of *Ex vivo* cultivated limbal epithelial stem cell on amniotic membrane in limbal stem cell deficiency. *Cornea* 2015; **34**: 592-600 [PMID: 25789694 DOI: 10.1097/ICO.0000000000000398]

135 **O'Callaghan AR**, Dziasko MA, Sheth-Shah R, Lewis MP, Daniels JT. Oral Mucosa Tissue Equivalents for the Treatment of Limbal Stem Cell Deficiency. *Adv Biosyst* 2020; **4**: e1900265 [PMID: 32515079 DOI: 10.1002/adbi.201900265]

136 **Sheth R**, Neale MH, Shortt AJ, Massie I, Vernon AJ, Daniels JT. Culture and Characterization of Oral Mucosal Epithelial Cells on a Fibrin Gel for Ocular Surface Reconstruction. *Curr Eye Res* 2015; **40**: 1077-1087 [PMID: 25380127 DOI: 10.3109/02713683.2014.978477]

137 **He J**, Ou S, Ren J, Sun H, He X, Zhao Z, Wu H, Qu Y, Liu T, Jeyalatha V, Zhang L, Li Q, Reinach PS, Quantock A, Hao J, Liu Z, Li W. Tissue engineered corneal epithelium derived from clinical-grade human embryonic stem cells. *Ocul Surf* 2020; **18**: 672-680 [PMID: 32710961 DOI: 10.1016/j.jtos.2020.07.009]

138 **Zhu J**, Slevin M, Guo BQ, Zhu SR. Induced pluripotent stem cells as a potential therapeutic source for corneal epithelial stem cells. *Int J Ophthalmol* 2018; **11**: 2004-2010 [PMID: 30588437 DOI: 10.18240/ijo.2018.12.21]

139 **Kamarudin TA**, Bojic S, Collin J, Yu M, Alharthi S, Buck H, Shortt A, Armstrong L, Figueiredo FC, Lako M. Differences in the Activity of Endogenous Bone Morphogenetic Protein Signaling Impact on the Ability of Induced Pluripotent Stem Cells to Differentiate to Corneal Epithelial-Like Cells. *Stem Cells* 2018; **36**: 337-348 [PMID: 29226476 DOI: 10.1002/stem.2750]

140 **Venugopal B**, Shenoy SJ, Mohan S, Anil Kumar PR, Kumary TV. Bioengineered corneal epithelial cell sheet from mesenchymal stem cells-A functional alternative to limbal stem cells for ocular surface reconstruction. *J Biomed Mater Res B Appl Biomater* 2020; **108**: 1033-1045 [PMID: 31400069 DOI: 10.1002/jbm.b.34455]

141 **Galindo S**, de la Mata A, López-Paniagua M, Herreras JM, Pérez I, Calonge M, Nieto-Miguel T. Subconjunctival injection of mesenchymal stem cells for corneal failure due to limbal stem cell deficiency: state of the art. *Stem Cell Res Ther* 2021; **12**: 60 [PMID: 33441175 DOI: 10.1186/s13287-020-02129-0]

142 **Patil S**, D'Souza C, Patil P, Patil V, Prabhu M, Bargale A, Kaveeshwar V, Kumar S, Shetty P. Culture and characterization of human dental pulp‑derived stem cells as limbal stem cells for corneal damage repair. *Mol Med Rep* 2019; **20**: 4688-4694 [PMID: 31545477 DOI: 10.3892/mmr.2019.10691]

143 **Hassan NT**, AbdelAziz NA. Oral Mucosal Stem Cells, Human Immature Dental Pulp Stem Cells and Hair Follicle Bulge Stem Cells as Adult Stem Cells Able to Correct Limbal Stem Cell Deficiency. *Curr Stem Cell Res Ther* 2018; **13**: 356-361 [PMID: 29473525 DOI: 10.2174/1574888X13666180223124936]

144 **Yamada K**, Young RD, Lewis PN, Shinomiya K, Meek KM, Kinoshita S, Caterson B, Quantock AJ. Mesenchymal-epithelial cell interactions and proteoglycan matrix composition in the presumptive stem cell niche of the rabbit corneal limbus. *Mol Vis* 2015; **21**: 1328-1339 [PMID: 26788025]

145 **Al-Jaibaji O**, Swioklo S, Connon CJ. Mesenchymal stromal cells for ocular surface repair. *Expert Opin Biol Ther* 2019; **19**: 643-653 [PMID: 30979344 DOI: 10.1080/14712598.2019.1607836]

146 **Kang SK**, Shin IS, Ko MS, Jo JY, Ra JC. Journey of mesenchymal stem cells for homing: strategies to enhance efficacy and safety of stem cell therapy. *Stem Cells Int* 2012; **2012**: 342968 [PMID: 22754575 DOI: 10.1155/2012/342968]

147 **Karp JM**, Leng Teo GS. Mesenchymal stem cell homing: the devil is in the details. *Cell Stem Cell* 2009; **4**: 206-216 [PMID: 19265660 DOI: 10.1016/j.stem.2009.02.001]

148 **Gu S**, Xing C, Han J, Tso MO, Hong J. Differentiation of rabbit bone marrow mesenchymal stem cells into corneal epithelial cells in vivo and *Ex vivo*. *Mol Vis* 2009; **15**: 99-107 [PMID: 19156227]

149 **Ma Y**, Xu Y, Xiao Z, Yang W, Zhang C, Song E, Du Y, Li L. Reconstruction of chemically burned rat corneal surface by bone marrow-derived human mesenchymal stem cells. *Stem Cells* 2006; **24**: 315-321 [PMID: 16109757 DOI: 10.1634/stemcells.2005-0046]

150 **Nieto-Miguel T**, Galindo S, Reinoso R, Corell A, Martino M, Pérez-Simón JA, Calonge M. In vitro simulation of corneal epithelium microenvironment induces a corneal epithelial-like cell phenotype from human adipose tissue mesenchymal stem cells. *Curr Eye Res* 2013; **38**: 933-944 [PMID: 23767776 DOI: 10.3109/02713683.2013.802809]

151 **Setiawan M**, Tan XW, Goh TW, Hin-Fai Yam G, Mehta JS. Inhibiting glycogen synthase kinase-3 and transforming growth factor-β signaling to promote epithelial transition of human adipose mesenchymal stem cells. *Biochem Biophys Res Commun* 2017; **490**: 1381-1388 [PMID: 28698144 DOI: 10.1016/j.bbrc.2017.07.036]

152 **Park SH**, Kim KW, Chun YS, Kim JC. Human mesenchymal stem cells differentiate into keratocyte-like cells in keratocyte-conditioned medium. *Exp Eye Res* 2012; **101**: 16-26 [PMID: 22683947 DOI: 10.1016/j.exer.2012.05.009]

153 **Syed-Picard FN**, Du Y, Lathrop KL, Mann MM, Funderburgh ML, Funderburgh JL. Dental pulp stem cells: a new cellular resource for corneal stromal regeneration. *Stem Cells Transl Med* 2015; **4**: 276-285 [PMID: 25713466 DOI: 10.5966/sctm.2014-0115]

154 **Yamashita K**, Inagaki E, Hatou S, Higa K, Ogawa A, Miyashita H, Tsubota K, Shimmura S. Corneal Endothelial Regeneration Using Mesenchymal Stem Cells Derived from Human Umbilical Cord. *Stem Cells Dev* 2018; **27**: 1097-1108 [PMID: 29929442 DOI: 10.1089/scd.2017.0297]

155 **Takahashi K**, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 2006; **126**: 663-676 [PMID: 16904174 DOI: 10.1016/j.cell.2006.07.024]

156 **Takahashi K**, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 2007; **131**: 861-872 [PMID: 18035408 DOI: 10.1016/j.cell.2007.11.019]

157 **Susaimanickam PJ**, Maddileti S, Pulimamidi VK, Boyinpally SR, Naik RR, Naik MN, Reddy GB, Sangwan VS, Mariappan I. Generating minicorneal organoids from human induced pluripotent stem cells. *Development* 2017; **144**: 2338-2351 [PMID: 28559289 DOI: 10.1242/dev.143040]

158 **Foster JW**, Wahlin K, Adams SM, Birk DE, Zack DJ, Chakravarti S. Cornea organoids from human induced pluripotent stem cells. *Sci Rep* 2017; **7**: 41286 [PMID: 28128337 DOI: 10.1038/srep41286]

159 **Buznyk O**, Pasyechnikova N, Islam MM, Iakymenko S, Fagerholm P, Griffith M. Bioengineered Corneas Grafted as Alternatives to Human Donor Corneas in Three High-Risk Patients. *Clin Transl Sci* 2015; **8**: 558-562 [PMID: 25996570 DOI: 10.1111/cts.12293]

160 **Mi S**, Chen B, Wright B, Connon CJ. Plastic compression of a collagen gel forms a much improved scaffold for ocular surface tissue engineering over conventional collagen gels. *J Biomed Mater Res A* 2010; **95**: 447-453 [PMID: 20648540 DOI: 10.1002/jbm.a.32861]

161 **Di Iorio E**, Ferrari S, Fasolo A, Böhm E, Ponzin D, Barbaro V. Techniques for culture and assessment of limbal stem cell grafts. *Ocul Surf* 2010; **8**: 146-153 [PMID: 20712971 DOI: 10.1016/s1542-0124(12)70225-2]

162 **Tominac Trcin M**, Zdraveva E, Dolenec T, Vrgoč Zimić I, Bujić Mihica M, Batarilo I, Dekaris I, Blažević V, Slivac I, Holjevac Grgurić T, Bajsić EG, Markov K, Čanak I, Kuzmić S, Tarbuk A, Tomljenović A, Mrkonjić N, Mijović B. Poly(ε-caprolactone) Titanium Dioxide and Cefuroxime Antimicrobial Scaffolds for Cultivation of Human Limbal Stem Cells. *Polymers (Basel)* 2020; **12** [PMID: 32781567 DOI: 10.3390/polym12081758]

163 **Wang G**, Chen P, Wang Y, Wang Y, Reinach PS, Xue Y, Liu Z, Li C. Onion Epithelial Membrane Scaffolds Transfer Corneal Epithelial Layers in Reconstruction Surgery. *Adv Healthc Mater* 2020; **9**: e2000469 [PMID: 32548957 DOI: 10.1002/adhm.202000469]

164 **Lee H**, Lee JH, Hong S, Sunwoo JH, Kim HT, Kim ES, Kim JY, Hwang C, Tchah H. Transplantation of human corneal limbal epithelial cell sheet harvested on synthesized carboxymethyl cellulose and dopamine in a limbal stem cell deficiency. *J Tissue Eng Regen Med* 2021; **15**: 139-149 [PMID: 33210832 DOI: 10.1002/term.3159]

165 **Wang W**, Gao Q, Yu Z, Wang Y, Jiang M, Sun S, Wang P, Li Y, Meir YJ, Li G, Zhou H. Opening the Soul Window Manually: Limbal Tissue Scaffolds with Electrospun Polycaprolactone/Gelatin Nanocomposites. *Macromol Biosci* 2021; **21**: e2000300 [PMID: 33205604 DOI: 10.1002/mabi.202000300]

166 **Lai JY**, Ma DH. Glutaraldehyde cross-linking of amniotic membranes affects their nanofibrous structures and limbal epithelial cell culture characteristics. *Int J Nanomedicine* 2013; **8**: 4157-4168 [PMID: 24204144 DOI: 10.2147/IJN.S52731]

167 **Ma DH**, Lai JY, Cheng HY, Tsai CC, Yeh LK. Carbodiimide cross-linked amniotic membranes for cultivation of limbal epithelial cells. *Biomaterials* 2010; **31**: 6647-6658 [PMID: 20541801 DOI: 10.1016/j.biomaterials.2010.05.034]

168 **Lai JY**, Lue SJ, Cheng HY, Ma DH. Effect of matrix nanostructure on the functionality of carbodiimide cross-linked amniotic membranes as limbal epithelial cell scaffolds. *J Biomed Nanotechnol* 2013; **9**: 2048-2062 [PMID: 24266260 DOI: 10.1166/jbn.2013.1734]

169 **Lai JY**, Wang PR, Luo LJ, Chen ST. Stabilization of collagen nanofibers with L-lysine improves the ability of carbodiimide cross-linked amniotic membranes to preserve limbal epithelial progenitor cells. *Int J Nanomedicine* 2014; **9**: 5117-5130 [PMID: 25395849 DOI: 10.2147/IJN.S69689]

170 **Sekar S**, Sasirekha K, Krishnakumar S, Sastry TP. A novel cross-linked human amniotic membrane for corneal implantations. *Proc Inst Mech Eng H* 2013; **227**: 221-228 [PMID: 23662337 DOI: 10.1177/0954411912472423]

171 **Albert R**, Veréb Z, Csomós K, Moe MC, Johnsen EO, Olstad OK, Nicolaissen B, Rajnavölgyi E, Fésüs L, Berta A, Petrovski G. Cultivation and characterization of cornea limbal epithelial stem cells on lens capsule in animal material-free medium. *PLoS One* 2012; **7**: e47187 [PMID: 23056608 DOI: 10.1371/journal.pone.0047187]

172 **Freegard TJ**. The physical basis of transparency of the normal cornea. *Eye (Lond)* 1997; **11 ( Pt 4)**: 465-471 [PMID: 9425408 DOI: 10.1038/eye.1997.127]

173 **Pinnamaneni N**, Funderburgh JL. Concise review: Stem cells in the corneal stroma. *Stem Cells* 2012; **30**: 1059-1063 [PMID: 22489057 DOI: 10.1002/stem.1100]

174 **Shortt AJ**, Secker GA, Munro PM, Khaw PT, Tuft SJ, Daniels JT. Characterization of the limbal epithelial stem cell niche: novel imaging techniques permit in vivo observation and targeted biopsy of limbal epithelial stem cells. *Stem Cells* 2007; **25**: 1402-1409 [PMID: 17332511 DOI: 10.1634/stemcells.2006-0580]

175 **Du Y**, Carlson EC, Funderburgh ML, Birk DE, Pearlman E, Guo N, Kao WW, Funderburgh JL. Stem cell therapy restores transparency to defective murine corneas. *Stem Cells* 2009; **27**: 1635-1642 [PMID: 19544455 DOI: 10.1002/stem.91]

176 **Wu J**, Du Y, Mann MM, Funderburgh JL, Wagner WR. Corneal stromal stem cells versus corneal fibroblasts in generating structurally appropriate corneal stromal tissue. *Exp Eye Res* 2014; **120**: 71-81 [PMID: 24440595 DOI: 10.1016/j.exer.2014.01.005]

177 **Du Y**, Sundarraj N, Funderburgh ML, Harvey SA, Birk DE, Funderburgh JL. Secretion and organization of a cornea-like tissue in vitro by stem cells from human corneal stroma. *Invest Ophthalmol Vis Sci* 2007; **48**: 5038-5045 [PMID: 17962455 DOI: 10.1167/iovs.07-0587]

178 **Ghoubay D**, Borderie M, Grieve K, Martos R, Bocheux R, Nguyen TM, Callard P, Chédotal A, Borderie VM. Corneal stromal stem cells restore transparency after N2 injury in mice. *Stem Cells Transl Med* 2020; **9**: 917-935 [PMID: 32379938 DOI: 10.1002/sctm.19-0306]

179 **Hertsenberg AJ**, Shojaati G, Funderburgh ML, Mann MM, Du Y, Funderburgh JL. Corneal stromal stem cells reduce corneal scarring by mediating neutrophil infiltration after wounding. *PLoS One* 2017; **12**: e0171712 [PMID: 28257425 DOI: 10.1371/journal.pone.0171712]

180 **Bahn CF**, Falls HF, Varley GA, Meyer RF, Edelhauser HF, Bourne WM. Classification of corneal endothelial disorders based on neural crest origin. *Ophthalmology* 1984; **91**: 558-563 [PMID: 6462621 DOI: 10.1016/s0161-6420(84)34249-x]

181 **Bourne WM**, Nelson LR, Hodge DO. Central corneal endothelial cell changes over a ten-year period. *Invest Ophthalmol Vis Sci* 1997; **38**: 779-782 [PMID: 9071233]

182 **Schimmelpfennig BH**. Direct and indirect determination of nonuniform cell density distribution in human corneal endothelium. *Invest Ophthalmol Vis Sci* 1984; **25**: 223-229 [PMID: 6365828]

183 **Amann J**, Holley GP, Lee SB, Edelhauser HF. Increased endothelial cell density in the paracentral and peripheral regions of the human cornea. *Am J Ophthalmol* 2003; **135**: 584-590 [PMID: 12719063 DOI: 10.1016/s0002-9394(02)02237-7]

184 **Bednarz J**, Rodokanaki-von Schrenck A, Engelmann K. Different characteristics of endothelial cells from central and peripheral human cornea in primary culture and after subculture. *In Vitro Cell Dev Biol Anim* 1998; **34**: 149-153 [PMID: 9542652 DOI: 10.1007/s11626-998-0097-7]

185 **Paull AC**, Whikehart DR. Expression of the p53 family of proteins in central and peripheral human corneal endothelial cells. *Mol Vis* 2005; **11**: 328-334 [PMID: 15889017]

186 **Mimura T**, Joyce NC. Replication competence and senescence in central and peripheral human corneal endothelium. *Invest Ophthalmol Vis Sci* 2006; **47**: 1387-1396 [PMID: 16565372 DOI: 10.1167/iovs.05-1199]

187 **Senoo T**, Joyce NC. Cell cycle kinetics in corneal endothelium from old and young donors. *Invest Ophthalmol Vis Sci* 2000; **41**: 660-667 [PMID: 10711678]

188 **Zhu C**, Joyce NC. Proliferative response of corneal endothelial cells from young and older donors. *Invest Ophthalmol Vis Sci* 2004; **45**: 1743-1751 [PMID: 15161835 DOI: 10.1167/iovs.03-0814]

189 **Konomi K**, Zhu C, Harris D, Joyce NC. Comparison of the proliferative capacity of human corneal endothelial cells from the central and peripheral areas. *Invest Ophthalmol Vis Sci* 2005; **46**: 4086-4091 [PMID: 16249484 DOI: 10.1167/iovs.05-0245]

190 **Joyce NC**. Cell cycle status in human corneal endothelium. *Exp Eye Res* 2005; **81**: 629-638 [PMID: 16054624 DOI: 10.1016/j.exer.2005.06.012]

191 **Joyce NC**, Zhu CC, Harris DL. Relationship among oxidative stress, DNA damage, and proliferative capacity in human corneal endothelium. *Invest Ophthalmol Vis Sci* 2009; **50**: 2116-2122 [PMID: 19117931 DOI: 10.1167/iovs.08-3007]

192 **Whikehart DR**, Parikh CH, Vaughn AV, Mishler K, Edelhauser HF. Evidence suggesting the existence of stem cells for the human corneal endothelium. *Mol Vis* 2005; **11**: 816-824 [PMID: 16205623]

193 **McGowan SL**, Edelhauser HF, Pfister RR, Whikehart DR. Stem cell markers in the human posterior limbus and corneal endothelium of unwounded and wounded corneas. *Mol Vis* 2007; **13**: 1984-2000 [PMID: 17982423]

194 **Yam GH**, Seah X, Yusoff NZBM, Setiawan M, Wahlig S, Htoon HM, Peh GSL, Kocaba V, Mehta JS. Characterization of Human Transition Zone Reveals a Putative Progenitor-Enriched Niche of Corneal Endothelium. *Cells* 2019; **8** [PMID: 31614883 DOI: 10.3390/cells8101244]

195 **Hara S**, Hayashi R, Soma T, Kageyama T, Duncan T, Tsujikawa M, Nishida K. Identification and potential application of human corneal endothelial progenitor cells. *Stem Cells Dev* 2014; **23**: 2190-2201 [PMID: 24588720 DOI: 10.1089/scd.2013.0387]

196 **He Z**, Campolmi N, Gain P, Ha Thi BM, Dumollard JM, Duband S, Peoc'h M, Piselli S, Garraud O, Thuret G. Revisited microanatomy of the corneal endothelial periphery: new evidence for continuous centripetal migration of endothelial cells in humans. *Stem Cells* 2012; **30**: 2523-2534 [PMID: 22949402 DOI: 10.1002/stem.1212]

197 **Parikumar P**, John S, Senthilkumar R, Manjunath S, Baskar S, Haraguchi K, Abraham S. Successful transplantation of in vitro expanded human corneal endothelial precursors to corneal endothelial surface using a nanocomposite sheets. *J Stem Cells Regen Med* 2011; **7**: 94 [PMID: 24693181]

198 **Parikumar P**, Haraguchi K, Ohbayashi A, Senthilkumar R, Abraham SJ. Successful transplantation of in vitro expanded human cadaver corneal endothelial precursor cells on to a cadaver bovine's eye using a nanocomposite gel sheet. *Curr Eye Res* 2014; **39**: 522-526 [PMID: 24144454 DOI: 10.3109/02713683.2013.838633]

199 **Frausto RF**, Le DJ, Aldave AJ. Transcriptomic Analysis of Cultured Corneal Endothelial Cells as a Validation for Their Use in Cell Replacement Therapy. *Cell Transplant* 2016; **25**: 1159-1176 [PMID: 26337789 DOI: 10.3727/096368915X688948]

200 **Inagaki E**, Hatou S, Higa K, Yoshida S, Shibata S, Okano H, Tsubota K, Shimmura S. Skin-Derived Precursors as a Source of Progenitors for Corneal Endothelial Regeneration. *Stem Cells Transl Med* 2017; **6**: 788-798 [PMID: 28186681 DOI: 10.1002/sctm.16-0162]

201 **Shen L**, Sun P, Zhang C, Yang L, Du L, Wu X. Therapy of corneal endothelial dysfunction with corneal endothelial cell-like cells derived from skin-derived precursors. *Sci Rep* 2017; **7**: 13400 [PMID: 29042661 DOI: 10.1038/s41598-017-13787-1]

202 **Shao C**, Fu Y, Lu W, Fan X. Bone marrow-derived endothelial progenitor cells: a promising therapeutic alternative for corneal endothelial dysfunction. *Cells Tissues Organs* 2011; **193**: 253-263 [PMID: 20962503 DOI: 10.1159/000319797]

203 **Zhang K**, Pang K, Wu X. Isolation and transplantation of corneal endothelial cell-like cells derived from in-vitro-differentiated human embryonic stem cells. *Stem Cells Dev* 2014; **23**: 1340-1354 [PMID: 24499373 DOI: 10.1089/scd.2013.0510]

204 **Chen X**, Wu L, Li Z, Dong Y, Pei X, Huang Y, Wang L. Directed Differentiation of Human Corneal Endothelial Cells From Human Embryonic Stem Cells by Using Cell-Conditioned Culture Media. *Invest Ophthalmol Vis Sci* 2018; **59**: 3028-3036 [PMID: 30025120 DOI: 10.1167/iovs.17-23627]

**Footnotes**

**Conflict-of-interest statement:** The authors declare no conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** August 21, 2022

**First decision:** October 31, 2022

**Article in press:** November 23, 2022

**Specialty type:** Ophthalmology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Gaitanou M, Greece; Hassaan NA, Egypt; Zhang QY, China **S-Editor:** Chen YL **L-Editor:** A **P-Editor:** Chen YL

**Figure Legends**

图形用户界面, 应用程序

描述已自动生成

**Figure 1 Corneal stratification.** The corneal layer includes the epithelium, bowman membrane, stroma, Descemet membrane and endothelium.

**图示

描述已自动生成**

**Figure 2 Location of limbal stem cells and corneal stromal stem cells.** Limbal stem cells (LSCs) are located at the base of the limbus and are in close contact with niche cells, including melanocytes. LSCs are symmetrically divided into two identical cells in the horizontal plane or asymmetrically differentiated into another LSC and a transient amplifying cell (TAC) in both vertical and horizontal planes. Then, TACs are divided into postmitotic cells (PMCs) as they migrate centripetally. The PMCs are then differentiated into terminally differentiated cells (TDCs) and shed from the corneal surface. Corneal stromal stem cells are in the anterior stroma subjacent to the epithelial basement membrane, in regions where the basement membrane has muslimah and folds termed the Palisades of Vogt. LSC: Limbal stem cell; TAC: Transient amplifying cell; PMC: Postmitotic cell; TDC: Terminal differentiated cell; CSSC: Corneal stromal stem cell.

**Table 1 Culture conditions of limbal stem cells**

|  |  |  |  |
| --- | --- | --- | --- |
| **Culture condition** | **Canine amniotic membrane** | **Atelocollagen gel** | **Temperature-responsive culture dish** |
| Culture | | | |
| Adhesion time, d | 1 | 1 | 2 |
| Convergence time, d | 5 | 7 | 14 |
| Layers | 6-8 | 4-5 | 2-3 |
| Immunofluorescence | | | |
| Ki-67 | Basal layer + | Basal layer ++ | Basal layer - |
| K3 | Each layer + | Each layer except basal layer + | Each layer + |
| ABCG2 | Only in basal layer + | | |
| P63 | Basal layer + | 2-3 layers, including the basal layer + | Basal layer + |

**Table 2 Methods for the isolation of limbal stem cells**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Experimenter** | **Tissue** | **Isolation methods** | **Medium** | **Markers** |
| Yamamoto *et al*[42], 2010 | Human corneal epithelial stem/progenitor cells | 0.25% collagenase and accumax | Serum-free PCT corneal epithelium medium | P75 ntr2, p63, integrin β-1 |
| Albert *et al*[171], 2012 | Human cornea limbal epithelial stem cells | None | Human lens capsule | KRT8, KRT14, KRT3, KRT12, KRT19, VIM, MKI67, p63α, ABCG2, CK19, Vim, Itgα9, CK8/18, CK14 |
| Shaharuddin *et al*[43], 2014 | Human limbal epithelial cell | LSP protocol, Hoechst 33342 dye, Flow Cytometry Analysis and Fluorescence Activated Cell Sorting | None | ABCG2, ΔNp63, Sox2 |
| Nam *et al*[44], 2013 | Beagle limbal epithelial cells | None | Canine amniotic membrane | ABCG2, p63, vimentin |
| Moriyama *et al*[45], 2014 | Equine corneal epithelial stem cells | Dispase II and a 0.25% trypsin EDTA solution | Standard supplemented hormone epithelial medium | P63, CK14 |
| Nam *et al*[46], 2015 | Beagle limbal epithelial cells | Dispase II, trypsin | Canine amniotic membrane; atelocollagen gel; temperature-responsive culture dish | Ki-67, K3, ABCG2, P63 |
| López-Paniagua *et al*[60], 2016 | Human cornea limbal epithelial stem cells | 0.25% trypsin-EDTA | Biosafe IOBA-HS culture medium | K14, K15, ABCG2, p63α |
| Shirzadeh *et al*[61], 2018 | Human cornea limbal epithelial stem cells | Collagenase II and cold trypsin | Supplemental hormonal epithelial medium with husscs or 3T3 cells as feeder layers | ABCG2, ΔNP63-α, CK19, CK 3, CK12 |
| Li *et al*[62], 2021 | Human cornea limbal epithelial stem cells | 0.05% trypsin/1 mm EDTA solution | Standard supplemented hormone epithelial medium | TSPAN7, SOX17 |

SHEM: Supplemented hormone epithelial medium.

**Table 3 Causes of limbal stem cell deficiency**

|  |  |  |  |
| --- | --- | --- | --- |
| **Item** | **Causes** | | |
| Hereditary LSCD | Congenital aniridia[80,81] | | |
| Dyskeratosis congenital[82,83] | | |
| Xeroderma pigmentosum[84] | | |
| Peters’ anomaly[85] | | |
| Keratitis ichthyosis deafness syndrome[86] | | |
| Epidermolysis bullosa[87] | | |
| Acquired LSCD | Acquired nonimmune-mediated | Burns | Alkali burns[88,89] |
|  | Acid burns[90,91] |
|  | Thermal burns[92,93] |
|  | Radiation burns[94] |
| Infection | Viral keratitis[95] |
|  | Bacterial keratitis[96] |
|  | Trachoma[97,98] |
| Oncologic | Ocular surface tumours[99] |
| Iatrogenic | Cryotherapy[84,100] |
|  | Chemotherapeutic agents[101-103] |
|  | Surgeries in the limbic region[103,104] |
| Others | Contact lens use[105,106] |
|  | Bullous keratopathy[107] |
| Acquired primary immune-mediated | Stevens-Johnson syndrome[108] | |
|  |  | Mucous membrane pemphigoid[109,110] | |
|  |  | Vernal keratoconjunctivitis[111,112] | |
|  |  | Atopic keratoconjunctivitis[113] | |
|  |  | Graft-versus-host disease[114,115] | |

LSCD: Limbal stem cells deficiency.

**Table 4 Treatment strategies for limbal stem cell deficiency**

|  |  |  |  |
| --- | --- | --- | --- |
| **Treatment** | **Description** | | |
| Conservative treatment | Nonsurgical options | Autologous serum drops | |
| Therapeutic soft contact lens | |
| Therapeutic scleral lens | |
| Eye lubrication | |
| Surgical options | Corneal scraping | |
| Amniotic membrane transplantation | |
| Invasive treatment | Conjunctival limbal autograft | | |
| Conjunctival limbal allograft | | |
| Keratolimbal allograft | | |
| *Ex vivo* cultivated limbal epithelial stem cells | | |
| Simple limbal epithelial transplantation | | |
| Emerging alternative cell populations transplantation | Alternative cell populations | Oral mucosal epithelial cells |
| Human embryonic stem cells |
| Induced pluripotent stem cells |
| Mesenchymal stem cells |
| Human immature dental pulp stem cells |
| Alternative cell carriers/scaffolds | Modified HAM |
| Collagen |
| Fibrin |
| Siloxane hydrogel contact lenses |
| Human lens capsule |
| Poly (ε-caprolactone) |
| Onion epithelial membrane scaffolds |
| Carboxymethyl cellulose |
| Electrospun polycaprolactone/gelatine nanocomposites |



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**